	id	Topic_Num	Topic_Perc_Contribu	Topic_Keywords	Origin_Text	Text
0	44029	0.0	0.2935	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Hazard Ratio  (and 95% Confidence Intervals)  in Univariate and Multivariate Analysis of Predictors of Major Cardiac Events  (Cardiac Death or Worsening of Heart Failure Leading to Heart Transplantation)	['hazard', 'ratio', 'confid', 'interv', 'univari', 'multivari', 'analysi', 'predictor', 'major', 'cardiac', 'event', 'cardiac', 'death', 'worsen', 'heart', 'failur', 'lead', 'heart', 'transplant']
1	23344	0.0	0.2836	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Left Ventricular and Right Ventricular Ejection Fractions, Left Ventricular and Right Ventricular Mean Phases, Left-to-Right Mean Phase Difference  (L-RMP)  and Phase Standard Deviations for Both Ventricles in 30 Cases of Left Sided WPW legend	['leav', 'ventricular', 'right', 'ventricular', 'eject', 'fraction', 'leav', 'ventricular', 'right', 'ventricular', 'mean', 'phase', 'leav', 'right', 'mean', 'phase', 'differ', 'rmp', 'phase', 'standard', 'deviat', 'ventricl', 'case', 'leav', 'side', 'wpw']
2	41163	0.0	0.2817	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Partial Regression Coefficients  (All Subjects, n = 262)  for Forward Stepwise Linear Regression for Dependent Variables Augmentation Pressure and Augmentation Index    legend	['partial', 'regress', 'coeffici', 'subject', 'forward', 'stepwis', 'linear', 'regress', 'depend', 'variabl', 'augment', 'pressur', 'augment', 'index']
3	23343	0.0	0.2797	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Left Ventricular  (LVEF)  and Right Ventricular  (RVEF)  Ejection Fractions, Left Ventricular  (LVMP)  and Right Ventricular  (RVMP)  Mean Phases, Left-to-Right Mean Phase Difference  (L-RMP)  and Phase Standard Deviations  (LVPSD and RVPSD)  for Both Ventricles in 14 Cases of Right Sided WPW legend	['leav', 'ventricular', 'lvef', 'right', 'ventricular', 'rvef', 'eject', 'fraction', 'leav', 'ventricular', 'lvmp', 'right', 'ventricular', 'rvmp', 'mean', 'phase', 'leav', 'right', 'mean', 'phase', 'differ', 'rmp', 'phase', 'standard', 'deviat', 'lvpsd', 'rvpsd', 'ventricl', 'case', 'right', 'side', 'wpw']
4	24968	0.0	0.2782	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Predictors of Mortality by Multivariable Analysis: Variables Are Shown in the Order They Entered a Stepwise Cox Regression Model	['predictor', 'mortal', 'multivari', 'analysi', 'variabl', 'show', 'order', 'enter', 'stepwis', 'cox', 'regress', 'model']
5	43918	0.0	0.2774	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Logistic Regression Models for Pre- and Post-Transplant Predictors for Normalization of Left Ventricular Ejection Fraction  (LVEF 50%)  in the Post-Transplant Period  (Reference Group: Group With LVEF 50% in the Post-Transplant Period)	['logist', 'regress', 'model', 'pre', 'post', 'transplant', 'predictor', 'normal', 'leav', 'ventricular', 'eject', 'fraction', 'lvef', 'post', 'transplant', 'period', 'refer', 'group', 'group', 'lvef', 'post', 'transplant', 'period']
6	33660	0.0	0.2742	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Results of Survival Analysis  (Cox Proportional Hazards Model)  for the Combined End Point: Cardiac Mortality + Urgent Heart Transplantation + Readmission for Congestive Heart Failure	['result', 'surviv', 'analysi', 'cox', 'proport', 'hazard', 'model', 'combin', 'end', 'point', 'cardiac', 'mortal', 'urgent', 'heart', 'transplant', 'readmiss', 'congest', 'heart', 'failur']
7	42080	0.0	0.2725	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Impact of Normal Versus Reduced Left Ventricular Ejection Fraction on the Mortality of Congestive Heart Failure Cases: Results of Cox Proportional Hazards Regression Models	['impact', 'normal', 'versus', 'reduc', 'leav', 'ventricular', 'eject', 'fraction', 'mortal', 'congest', 'heart', 'failur', 'case', 'result', 'cox', 'proport', 'hazard', 'regress', 'model']
8	43914	0.0	0.2684	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Description of the Left Ventricular Ejection Fraction  (LVEF%)  at Different Time Periods: At the Time of Transplant Evaluation, While on the Waiting List to be Transplanted, and During the Follow-Up After Kidney Transplantation	['descript', 'leav', 'ventricular', 'eject', 'fraction', 'lvef', 'differ', 'time', 'period', 'time', 'transplant', 'evalu', 'wait', 'list', 'transplant', 'follow', 'kidney', 'transplant']
9	18857	0.0	0.2664	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Univariate Cox Regression Analysis and Cox Proportional Hazards Analysis of Predictors of Cardiac Death legend	['univari', 'cox', 'regress', 'analysi', 'cox', 'proport', 'hazard', 'analysi', 'predictor', 'cardiac', 'death']
10	20340	0.0	0.2629	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Gender-Specific Mean and Standard Deviation of LV Mass, End-Diastolic Volume, Stroke Volume, Ejection Fraction, and Cardiac Output by Cardiac MRI in MESA Participants	['gender', 'specif', 'mean', 'standard', 'deviat', 'lv', 'mass', 'end', 'diastol', 'volum', 'stroke', 'volum', 'eject', 'fraction', 'cardiac', 'output', 'cardiac', 'mri', 'mesa', 'particip']
11	31917	0.0	0.2615	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Results of Multiple Logistic Regression Analysis: Final Significant Variables in Equation Using Forward Stepwise Selection  (Wald)	['result', 'multipl', 'logist', 'regress', 'analysi', 'final', 'signific', 'variabl', 'equat', 'forward', 'stepwis', 'select', 'wald']
12	19970	0.0	0.2607	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multivariable Cox Proportional Regression Analysis Showing Significant Predictors of Outcome  (Death, Heart Transplant, or Left Ventricular Assist Device Implantation)  in Cardiac Resynchronization Therapy Patients	['multivari', 'cox', 'proport', 'regress', 'analysi', 'show', 'signific', 'predictor', 'outcom', 'death', 'heart', 'transplant', 'leav', 'ventricular', 'assist', 'devic', 'implant', 'cardiac', 'therapi', 'patient']
13	39564	0.0	0.2579	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multiple regression analysis using Cox's proportional hazards model to determine the influence of individual variables on survival in hypopituitarism	['multipl', 'regress', 'analysi', 'cox', 'proport', 'hazard', 'model', 'determin', 'influenc', 'individu', 'variabl', 'surviv', 'hypopituitar']
14	11779	0.0	0.2579	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	ORs and RRs  (95% Confidence Intervals)  for Other Correlates of Preserved Left Ventricular Systolic Function in Order of Entry Into the Full Logistic Model	['or', 'rrs', 'confid', 'interv', 'correl', 'preserv', 'leav', 'ventricular', 'systol', 'function', 'order', 'entri', 'logist', 'model']
15	34215	0.0	0.2575	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multiple Regression Analysis of Variables Associated With CD40L Levels; Entire Model  (Regression Summary for Dependent Variable: R2= 0.60, F = 5.58; p < 0.00005)  and Final Model With Stepwise Method	['multipl', 'regress', 'analysi', 'variabl', 'associ', 'cd', 'level', 'entir', 'model', 'regress', 'summari', 'depend', 'variabl', 'final', 'model', 'stepwis', 'method']
16	48923	0.0	0.2573	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Final multivariable Cox proportional hazards model of time to first late seizure in the derivation cohort	['final', 'multivari', 'cox', 'proport', 'hazard', 'model', 'time', 'late', 'seizur', 'deriv', 'cohort']
17	42229	0.0	0.2567	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Univariate and Multivariate Linear Model of Left Ventricular End-Diastolic Volume Index in 113 Patients With CHF legend	['univari', 'multivari', 'linear', 'model', 'leav', 'ventricular', 'end', 'diastol', 'volum', 'index', 'patient', 'chf']
18	5713	0.0	0.2566	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Logistic Regression Multivariate Independent Predictors of Spontaneous Conversion to Sinus Rhythm	['logist', 'regress', 'multivari', 'independ', 'predictor', 'spontan', 'convers', 'sinus', 'rhythm']
19	42436	0.0	0.2542	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Table of Regression Coefficients From a Multivariate Linear Regression Model for LV Mass-to-Volume Ratio	['regress', 'coeffici', 'multivari', 'linear', 'regress', 'model', 'lv', 'mass', 'volum', 'ratio']
20	11796	0.0	0.2539	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Univariate and Multivariate Cox Proportional Hazard Analyses for the Identification of Patients With Chronic Heart Failure at Risk for Cardiac Events	['univari', 'multivari', 'cox', 'proport', 'hazard', 'analys', 'identif', 'patient', 'chronic', 'heart', 'failur', 'risk', 'cardiac', 'event']
21	32882	0.0	0.2537	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Variables Independently Associated With In-Hospital Mortality Adjusted by Risk in a Multivariable Logistic Regression Model and a Multilevel Model, With Odds Ratio and 95% Confidence Intervals for Each Variable	['variabl', 'independ', 'associ', 'hospit', 'mortal', 'adjust', 'risk', 'multivari', 'logist', 'regress', 'model', 'multilevel', 'model', 'odd', 'ratio', 'confid', 'interv', 'variabl']
22	36842	0.0	0.253	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Cox proportional hazards regression model for individual factors affecting graft failure in first-time recipients of kidneys from cardiac-death donors, adjusted for age of donors and recipients, and cold ischaemic time	['cox', 'proport', 'hazard', 'regress', 'model', 'individu', 'factor', 'affect', 'graft', 'failur', 'time', 'recipi', 'kidney', 'cardiac', 'death', 'donor', 'adjust', 'age', 'donor', 'recipi', 'cold', 'ischaem', 'time']
23	11298	0.0	0.2523	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Final Multivariable Cox Proportional Hazards Model  (Global Chi-Square of the Model = 1,146.1, p < 0.001)	['final', 'multivari', 'cox', 'proport', 'hazard', 'model', 'global', 'chi', 'squar', 'model']
24	4385	0.0	0.252	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multivariate Stepwise Cox Regression Analysis of Potential Risk Variables in Order to Detect Independent Predictors of Cardiac Death or Acute Myocardial Infarction at 30 Days legend	['multivari', 'stepwis', 'cox', 'regress', 'analysi', 'potenti', 'risk', 'variabl', 'order', 'detect', 'independ', 'predictor', 'cardiac', 'death', 'acut', 'myocardi', 'infarct', 'day']
25	4501	0.0	0.2513	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Intervals Measured During Ventricular Tachycardia, Responses to Pacing During Ventricular Tachycardia and Sinus Rhythm and Presence of Isolated Diastolic Potential During Sinus Rhythm	['interv', 'measur', 'ventricular', 'tachycardia', 'respons', 'pace', 'ventricular', 'tachycardia', 'sinus', 'rhythm', 'presenc', 'isol', 'diastol', 'potenti', 'sinus', 'rhythm']
26	42079	0.0	0.2513	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Impact of Congestive Heart Failure on Mortality: Results of Multivariable Cox Proportional Hazards Regression Models legend	['impact', 'congest', 'heart', 'failur', 'mortal', 'result', 'multivari', 'cox', 'proport', 'hazard', 'regress', 'model']
27	42977	0.0	0.25	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multivariable Analysis for Independent Predictors of Survival in HFpEF Patients  (Cox Proportional Hazard Model)	['multivari', 'analysi', 'independ', 'predictor', 'surviv', 'hfpef', 'patient', 'cox', 'proport', 'hazard', 'model']
28	42556	0.0	0.25	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multiple Linear Regression Analysis Assessing the Independent Influence of Different Variables on Natriuretic Peptides	['multipl', 'linear', 'regress', 'analysi', 'assess', 'independ', 'influenc', 'differ', 'variabl', 'natriuret', 'peptid']
29	20372	0.0	0.25	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multiple Regression Analysis of the Relationship Between Left Ventricular Mass Index and Other Variables for the Entire Group	['multipl', 'regress', 'analysi', 'relationship', 'leav', 'ventricular', 'mass', 'index', 'variabl', 'entir', 'group']
30	36841	0.0	0.2496	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Cox proportional hazards regression model for graft failure in first-time recipients of kidneys from cardiac-death donors, adjusted for age of donors and recipients, and cold ischaemic time	['cox', 'proport', 'hazard', 'regress', 'model', 'graft', 'failur', 'time', 'recipi', 'kidney', 'cardiac', 'death', 'donor', 'adjust', 'age', 'donor', 'recipi', 'cold', 'ischaem', 'time']
31	31099	0.0	0.2492	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Partial Correlation Coefficients  (r) , Controlled for Age, of Body Size, Body Composition and Blood Pressure With Unindexed and Indexed Left Ventricular Mass  (LVM)	['partial', 'correl', 'coeffici', 'control', 'age', 'bodi', 'size', 'bodi', 'composit', 'blood', 'pressur', 'unindex', 'index', 'leav', 'ventricular', 'mass', 'lvm']
32	30663	0.0	0.2491	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multiple Linear Regression Analysis Results With Augmentation Index as the Dependent Variable  a	['multipl', 'linear', 'regress', 'analysi', 'result', 'augment', 'index', 'depend', 'variabl']
33	7980	0.0	0.2482	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multivariate Cox Proportional Hazards Regression Model of Significant Predictors of Death or Heart Failure	['multivari', 'cox', 'proport', 'hazard', 'regress', 'model', 'signific', 'predictor', 'death', 'heart', 'failur']
34	9204	0.0	0.2475	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Results of Multivariable Modeling: Hazard Ratios, 95% Confidence Intervals and p Values for Significant Multivariable Predictors of Outcome in Models That Incorporate Echocardiographic, Clinical and Hemodynamic Variables	['result', 'multivari', 'model', 'hazard', 'ratio', 'confid', 'interv', 'valu', 'signific', 'multivari', 'predictor', 'outcom', 'model', 'incorpor', 'clinic', 'hemodynam', 'variabl']
35	20416	0.0	0.2471	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Differences Among End-Diastolic Volume, End-Systolic Volume, Ejection Fraction and Left Ventricular Mass as Revealed on Cine MRI and Real-Time MRI legend	['differ', 'end', 'diastol', 'volum', 'end', 'systol', 'volum', 'eject', 'fraction', 'leav', 'ventricular', 'mass', 'reveal', 'cine', 'mri', 'real', 'time', 'mri']
36	7301	0.0	0.2471	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Analysis of Significance and Prognostic Value of End-Diastolic Volume, Stroke Volume, Left Ventricular Ejection Fraction and Heart Rate Obtained During Dobutamine Infusion  a	['analysi', 'signific', 'prognost', 'valu', 'end', 'diastol', 'volum', 'stroke', 'volum', 'leav', 'ventricular', 'eject', 'fraction', 'heart', 'rate', 'obtain', 'dobutamin', 'infus']
37	32400	0.0	0.2464	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multivariate Logistic Regression Analyses to Assess the Predictive Value of Electrocardiographic Strain for the Presence of LVH, Abnormal LV Geometry and Abnormal LV Midwall Function in Patients With and Without Evident CHD    legend	['multivari', 'logist', 'regress', 'analys', 'assess', 'predict', 'valu', 'strain', 'presenc', 'lvh', 'abnorm', 'lv', 'geometri', 'abnorm', 'lv', 'midwal', 'function', 'patient', 'evid', 'chd']
38	28817	0.0	0.24600000000000002	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Final Multivariable Cox Regression Model of Predictors of Death Among 1,953 Children With DCM Not Undergoing Heart Transplantation	['final', 'multivari', 'cox', 'regress', 'model', 'predictor', 'death', 'children', 'dcm', 'undergo', 'heart', 'transplant']
39	42978	0.0	0.24600000000000002	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multivariable Analysis for Independent Predictors of Survival in HFpEF Patients With CAD  (Cox Proportional Hazard Model)	['multivari', 'analysi', 'independ', 'predictor', 'surviv', 'hfpef', 'patient', 'cad', 'cox', 'proport', 'hazard', 'model']
40	39643	0.0	0.24600000000000002	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Cox proportional hazard analysis for the effect of covariates on survival in patients with chronic heart failure  (SOLVD)	['cox', 'proport', 'hazard', 'analysi', 'effect', 'covari', 'surviv', 'patient', 'chronic', 'heart', 'failur', 'solvd']
41	30530	0.0	0.24600000000000002	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multiple Linear Regression Analysis of Clinical and Hemodynamic Variables and Follow-Up Left Ventricular Ejection Fraction  legend	['multipl', 'linear', 'regress', 'analysi', 'clinic', 'hemodynam', 'variabl', 'follow', 'leav', 'ventricular', 'eject', 'fraction']
42	17885	0.0	0.24600000000000002	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Odds Ratios  (With 95% Confidence Intervals)  for Univariate Predictors of Mortality and for Those Same Predictors Together With Log10Troponin in Bivariate Models	['odd', 'ratio', 'confid', 'interv', 'univari', 'predictor', 'mortal', 'predictor', 'log', 'troponin', 'bivari', 'model']
43	24732	0.0	0.2457	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multivariate Cox Proportional Hazards Models for Prediction of Time to Recurrence legend	['multivari', 'cox', 'proport', 'hazard', 'model', 'predict', 'time', 'recurr']
44	31390	0.0	0.2457	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Univariate and Multivariate Analysis of Predictive Variables for log Vo 2max/kg2/3	['univari', 'multivari', 'analysi', 'predict', 'variabl', 'log', 'vo', 'max']
45	43635	0.0	0.2448	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Cox Proportional Hazard Models for MR-proANP and NT-proBNP to Predict Survival in Different Subgroups of Patients With Chronic Heart Failure  (Derivation and Validation Samples Combined)	['cox', 'proport', 'hazard', 'model', 'mr', 'proanp', 'nt', 'probnp', 'predict', 'surviv', 'differ', 'subgroup', 'patient', 'chronic', 'heart', 'failur', 'deriv', 'valid', 'sampl', 'combin']
46	33805	0.0	0.2425	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Computer Directed and Clinically Directed Stepwise Multiple Logistic Regression and Cox Proportion Hazard Analysis of Determinants of Hard Events in Medically Treated Patients legend	['direct', 'clinic', 'direct', 'stepwis', 'multipl', 'logist', 'regress', 'cox', 'proport', 'hazard', 'analysi', 'determin', 'hard', 'event', 'medic', 'treat', 'patient']
47	40905	0.0	0.2421	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multivariate analysis of predictors of ventricular tachycardia, sudden death, and atrial flutter/fibrillation after repair of tetralogy of Fallot	['multivari', 'analysi', 'predictor', 'ventricular', 'tachycardia', 'sudden', 'death', 'atrial', 'flutter', 'fibril', 'repair', 'tetralog', 'fallot']
48	28816	0.0	0.2421	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Unadjusted Cox Proportional Hazards Regression Analysis of Predictors of Death Among 1,953 Children With DCM Not Undergoing Heart Transplantation	['unadjust', 'cox', 'proport', 'hazard', 'regress', 'analysi', 'predictor', 'death', 'children', 'dcm', 'undergo', 'heart', 'transplant']
49	23679	0.0	0.2415	analysi, multivari, regress, variabl, model, predictor, cardiac, time, univari, heart	Multivariate Cox Regression Analyses for Peak Vo 2and Ve/Vco 2Slope	['multivari', 'cox', 'regress', 'analys', 'peak', 'vo', 've', 'vco', 'slope']
50	21319	1.0	0.3755	number, effect, estim, case, women, level, intervent, health, total, region	Potential effect of the internet on physical activity interventions  (based on effect estimates from web-based physical activity interventions and other physical activity interventions)  and the potential effect of mobile phones on physical activity interventions  (based on effect estimates from telephone-based physical activity interventions and from other physical activity interventions) , by country income	['potenti', 'effect', 'internet', 'physic', 'activ', 'intervent', 'base', 'effect', 'estim', 'web', 'base', 'physic', 'activ', 'intervent', 'physic', 'activ', 'intervent', 'potenti', 'effect', 'mobil', 'phone', 'physic', 'activ', 'intervent', 'base', 'effect', 'estim', 'telephon', 'base', 'physic', 'activ', 'intervent', 'physic', 'activ', 'intervent', 'countri', 'incom']
51	37917	1.0	0.3733	number, effect, estim, case, women, level, intervent, health, total, region	Analysis of trends from 19992002 and 200306 for government health expenditure as source  (GHE-S) ; share of general government expenditure spent on health  (GHE-S/GGE) ; share of gross domestic product  (GDP)  spent by government  (GGE/GDP) ; and GDP	['analysi', 'trend', 'govern', 'health', 'expenditur', 'sourc', 'ghe', 'share', 'general', 'govern', 'expenditur', 'spend', 'health', 'ghe', 'gge', 'share', 'gross', 'domest', 'product', 'gdp', 'spend', 'govern', 'gge', 'gdp', 'gdp']
52	21038	1.0	0.3677	number, effect, estim, case, women, level, intervent, health, total, region	Changes between 2012 and 2017 in the modern contraceptive prevalence rate  (mCPR) , unmet need for modern methods, demand satisfied with modern methods, and the number of women of reproductive age who are married or in a union using modern methods of contraception	['chang', 'modern', 'contracept', 'preval', 'rate', 'mcpr', 'unmet', 'need', 'modern', 'method', 'demand', 'satisfi', 'modern', 'method', 'number', 'women', 'reproduct', 'age', 'marri', 'union', 'modern', 'method', 'contracept']
53	32237	1.0	0.3461	number, effect, estim, case, women, level, intervent, health, total, region	Postprandial Changes of Nitrates/Nitrites, Lipoperoxides, and 8-epi Prostaglandin Plasma Levels After the Ingestion of a Phenol-Rich Olive Oil Meal  (400 ppm)  as Compared to a Low Phenol Olive Oil Meal  (80 ppm)	['postprandi', 'chang', 'nitrat', 'nitrit', 'lipoperoxid', 'epi', 'prostaglandin', 'plasma', 'level', 'ingest', 'phenol', 'rich', 'oliv', 'oil', 'meal', 'ppm', 'compar', 'low', 'phenol', 'oliv', 'oil', 'meal', 'ppm']
54	16272	1.0	0.3225	number, effect, estim, case, women, level, intervent, health, total, region	Analysis of association between receipt of financial assistance from Janani Suraksha Yojana and intervention coverage and health outcomes by use of two analytical approaches by high-focus, northeast, and non-high-focus states	['analysi', 'associ', 'receipt', 'financi', 'assist', 'janani', 'suraksha', 'yojana', 'intervent', 'coverag', 'health', 'outcom', 'use', 'analyt', 'approach', 'high', 'focus', 'northeast', 'non', 'high', 'focus', 'state']
55	13849	1.0	0.322	number, effect, estim, case, women, level, intervent, health, total, region	Number  (millions)  of women with an unmet need for modern methods and proportion of those wanting to avoid pregnancy with unmet need for modern methods, by region and subregion and by country income, in 2003, 2008, and 2012	['number', 'million', 'women', 'unmet', 'need', 'modern', 'method', 'proport', 'want', 'avoid', 'pregnanc', 'unmet', 'need', 'modern', 'method', 'region', 'subregion', 'countri', 'incom']
56	21629	1.0	0.319	number, effect, estim, case, women, level, intervent, health, total, region	Aggregate official development assistance to maternal, newborn, and child health, to child health per child, and to maternal and newborn health per livebirth in 2005 and 2006, and percentage change for the two categories between 2003 and 2006	['aggreg', 'offici', 'develop', 'assist', 'matern', 'newborn', 'child', 'health', 'child', 'health', 'child', 'matern', 'newborn', 'health', 'livebirth', 'percentag', 'chang', 'categori']
57	16264	1.0	0.3172	number, effect, estim, case, women, level, intervent, health, total, region	Official development assistance to child health per child and to maternal and neonatal health per livebirth, total to maternal, newborn, and child health in 2007 and 2008, and trends statistics, 200308	['offici', 'develop', 'assist', 'child', 'health', 'child', 'matern', 'neonat', 'health', 'livebirth', 'total', 'matern', 'newborn', 'child', 'health', 'trend', 'statist']
58	16263	1.0	0.3147	number, effect, estim, case, women, level, intervent, health, total, region	Official development assistance to maternal, newborn, and child health by aid modality and project purpose for the 68 Countdown priority countries, 200308	['offici', 'develop', 'assist', 'matern', 'newborn', 'child', 'health', 'aid', 'modal', 'project', 'purpos', 'countdown', 'prioriti', 'countri']
59	22093	1.0	0.3112	number, effect, estim, case, women, level, intervent, health, total, region	Official development assistance to maternal, newborn, and child health to the 74 Countdown priority countries by type of aid and purpose of projects between 2003 and 2010	['offici', 'develop', 'assist', 'matern', 'newborn', 'child', 'health', 'countdown', 'prioriti', 'countri', 'type', 'aid', 'purpos', 'project']
60	12388	1.0	0.3109	number, effect, estim, case, women, level, intervent, health, total, region	Effects of varying selected assumptions on the estimated additional annual running costs of providing child survival interventions at universal coverage, from reported levels in 2000  (US$5134 million)	['effect', 'vari', 'select', 'assumpt', 'estim', 'addit', 'annual', 'run', 'cost', 'provid', 'child', 'surviv', 'intervent', 'univers', 'coverag', 'report', 'level', 'million']
61	37918	1.0	0.3095	number, effect, estim, case, women, level, intervent, health, total, region	Time-series cross-sectional regression results for government health expenditure as source  (GHE-S)  as a share of gross domestic product  (GDP)  for countries in Global Burden of Disease developing regions based on the Arellano-Bover/Blundell-Bond model	['time', 'seri', 'cross', 'section', 'regress', 'result', 'govern', 'health', 'expenditur', 'sourc', 'ghe', 'share', 'gross', 'domest', 'product', 'gdp', 'countri', 'global', 'burden', 'diseas', 'develop', 'region', 'base', 'arellano', 'bover', 'blundel', 'bond', 'model']
62	21037	1.0	0.3047	number, effect, estim, case, women, level, intervent, health, total, region	Modern contraceptive prevalence rate  (mCPR) , unmet need for modern methods, and demand satisfied with modern methods in 2017 for 68 Family Planning 2020 countries	['modern', 'contracept', 'preval', 'rate', 'mcpr', 'unmet', 'need', 'modern', 'method', 'demand', 'satisfi', 'modern', 'method', 'famili', 'plan', 'countri']
63	17087	1.0	0.304	number, effect, estim, case, women, level, intervent, health, total, region	Numbers and incident rate ratios for recorded referrals and identifications of women experiencing domestic violence in general practice and domestic violence referrals received by specialist agencies, 12 months after intervention	['number', 'incid', 'rate', 'ratio', 'record', 'referr', 'identif', 'women', 'experi', 'domest', 'violenc', 'general', 'practic', 'domest', 'violenc', 'referr', 'receiv', 'specialist', 'agenc', 'month', 'intervent']
64	13847	1.0	0.3008	number, effect, estim, case, women, level, intervent, health, total, region	Number  (millions)  of women using modern methods and proportion of those wanting to avoid pregnancy using modern methods, by region and subregion and by country income in 2003, 2008, and 2012	['number', 'million', 'women', 'modern', 'method', 'proport', 'want', 'avoid', 'pregnanc', 'modern', 'method', 'region', 'subregion', 'countri', 'incom']
65	12386	1.0	0.3008	number, effect, estim, case, women, level, intervent, health, total, region	Estimated annual running costs of providing preventive interventions for child survival at 2000 coverage levels and universal coverage levels	['estim', 'annual', 'run', 'cost', 'provid', 'prevent', 'intervent', 'child', 'surviv', 'coverag', 'level', 'univers', 'coverag', 'level']
66	6761	1.0	0.2994	number, effect, estim, case, women, level, intervent, health, total, region	Antipneumococcal IgG antibody responses 1 month after booster vaccination with PHiD-CV and DTPa-HBV-IPV/Hib with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	['igg', 'antibodi', 'respons', 'month', 'booster', 'vaccin', 'phid', 'cv', 'dtpa', 'hbv', 'ipv', 'hib', 'prophylact', 'administr', 'paracetamol', 'atp', 'immunogen', 'cohort']
67	16261	1.0	0.299	number, effect, estim, case, women, level, intervent, health, total, region	Official development assistance to maternal, newborn, and child health by type and source of aid flow for the 68 Countdown priority countries, 200308	['offici', 'develop', 'assist', 'matern', 'newborn', 'child', 'health', 'type', 'sourc', 'aid', 'flow', 'countdown', 'prioriti', 'countri']
68	17048	1.0	0.2973	number, effect, estim, case, women, level, intervent, health, total, region	Health service resource use: mean  (SD)  resource use per patient and unit costs of resource items by type of care  (UK, 2009 prices)	['health', 'servic', 'resourc', 'use', 'mean', 'sd', 'resourc', 'use', 'patient', 'unit', 'cost', 'resourc', 'item', 'type', 'care', 'uk', 'price']
69	13287	1.0	0.2962	number, effect, estim, case, women, level, intervent, health, total, region	Antibodies to neuronal antigens in cerebellar syndromes   Sera were screened by routine immunohistochemistry on frozen sections of rat cerebellum and positive staining patterns1 were confirmed, as appropriate, by western blotting on rat cerebellar extracts or recombinant Hu or Yo polypeptides. VGCC antibodies were measured by immunoprecipitation of 125I--conotoxin MVIIC-labelled VGCCs extracted from human cerebellum,  2   and antibodies to glutamic acid decarboxylase measured with a commercial kit  (RSR Ltd, Cardiff, UK) .	['antibodi', 'neuron', 'antigen', 'cerebellar', 'syndrom', 'sera', 'screen', 'routin', 'freez', 'section', 'rat', 'cerebellum', 'posit', 'stain', 'pattern', 'confirm', 'appropri', 'western', 'blot', 'rat', 'cerebellar', 'extract', 'recombin', 'hu', 'yo', 'polypeptid', 'vgcc', 'antibodi', 'measur', 'conotoxin', 'mviic', 'label', 'vgccs', 'extract', 'human', 'cerebellum', 'antibodi', 'glutam', 'acid', 'decarboxylas', 'measur', 'commerci', 'kit', 'rsr', 'cardiff', 'uk']
70	15326	1.0	0.2934	number, effect, estim, case, women, level, intervent, health, total, region	Direct health-care costs attributable to physical inactivity paid by the public sector, private sector, and households, by country and WHO region  (in 1000 Int$, 2013)	['direct', 'health', 'care', 'cost', 'attribut', 'physic', 'inact', 'pay', 'public', 'sector', 'privat', 'sector', 'household', 'countri', 'region', 'int']
71	12833	1.0	0.2926	number, effect, estim, case, women, level, intervent, health, total, region	Ranking of research priorities for development of interventions to reduce stillbirths in low-income and middle-income countries	['rank', 'research', 'prioriti', 'develop', 'intervent', 'reduc', 'stillbirth', 'low', 'incom', 'middl', 'incom', 'countri']
72	41074	1.0	0.2908	number, effect, estim, case, women, level, intervent, health, total, region	Rankings of research priorities for implementation of interventions to reduce stillbirths in low-income and middle-income countries by 2015	['rank', 'research', 'prioriti', 'implement', 'intervent', 'reduc', 'stillbirth', 'low', 'incom', 'middl', 'incom', 'countri']
73	21627	1.0	0.2908	number, effect, estim, case, women, level, intervent, health, total, region	Worldwide official development assistance to maternal, newborn, and child health by type of aid and purpose of projects between 2003 and 2006	['worldwid', 'offici', 'develop', 'assist', 'matern', 'newborn', 'child', 'health', 'type', 'aid', 'purpos', 'project']
74	21941	1.0	0.2908	number, effect, estim, case, women, level, intervent, health, total, region	Official development assistance to reproductive health to the 74 Countdown priority countries by type of aid and purpose of projects, 200910	['offici', 'develop', 'assist', 'reproduct', 'health', 'countdown', 'prioriti', 'countri', 'type', 'aid', 'purpos', 'project']
75	6762	1.0	0.2873	number, effect, estim, case, women, level, intervent, health, total, region	OPA responses 1 month after booster vaccination with PHiD-CV and DTPa-HBV-IPV/Hib with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	['opa', 'respons', 'month', 'booster', 'vaccin', 'phid', 'cv', 'dtpa', 'hbv', 'ipv', 'hib', 'prophylact', 'administr', 'paracetamol', 'atp', 'immunogen', 'cohort']
76	37145	1.0	0.2862	number, effect, estim, case, women, level, intervent, health, total, region	Estimated number of neonatal deaths in 75 countries by region that could be averted by universal  (99% coverage)  delivery of all  *   evidence-based interventions	['estim', 'number', 'neonat', 'death', 'countri', 'region', 'avert', 'univers', 'coverag', 'deliveri', 'evid', 'base', 'intervent']
77	13848	1.0	0.2862	number, effect, estim, case, women, level, intervent, health, total, region	Percentage distribution of women in developing countries using modern contraceptives, by type of method, region and subregion, and country income, in 2003, 2008, and 2012	['percentag', 'distribut', 'women', 'develop', 'countri', 'modern', 'contracept', 'type', 'method', 'region', 'subregion', 'countri', 'incom']
78	6758	1.0	0.2852	number, effect, estim, case, women, level, intervent, health, total, region	Antipneumococcal IgG antibody responses 1 month after primary vaccination with PHiD-CV, DTPa-HBV-IPV/Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	['igg', 'antibodi', 'respons', 'month', 'primari', 'vaccin', 'phid', 'cv', 'dtpa', 'hbv', 'ipv', 'hib', 'human', 'rotavirus', 'vaccin', 'prophylact', 'administr', 'paracetamol', 'atp', 'immunogen', 'cohort']
79	12387	1.0	0.2834	number, effect, estim, case, women, level, intervent, health, total, region	Estimated annual running costs of delivering treatment interventions for child survival at 2000 coverage levels and universal coverage levels	['estim', 'annual', 'run', 'cost', 'deliv', 'treatment', 'intervent', 'child', 'surviv', 'coverag', 'level', 'univers', 'coverag', 'level']
80	7225	1.0	0.2828	number, effect, estim, case, women, level, intervent, health, total, region	Neglected low-cost opportunities and high-cost interventions in south Asia and sub-Saharan Africa	['neglect', 'low', 'cost', 'opportun', 'high', 'cost', 'intervent', 'south', 'asia', 'sub', 'saharan', 'africa']
81	21050	1.0	0.2825	number, effect, estim, case, women, level, intervent, health, total, region	Estimates and uncertainty intervals of the number of MWRA  (millions)  aged 1549 years, for total contraceptive use, unmet need, total demand, and unmet need for modern methods, for 2010 and 2015	['estim', 'uncertainti', 'interv', 'number', 'mwra', 'million', 'age', 'year', 'total', 'contracept', 'use', 'unmet', 'need', 'total', 'demand', 'unmet', 'need', 'modern', 'method']
82	40854	1.0	0.2822	number, effect, estim, case, women, level, intervent, health, total, region	Serum-antibody concentrations against capsular polysaccharide of Haemophilus influenzae type b  (PRP)  in Chilean infants given different primary immunisation regimens of PRP-T and PRP-CRM197 conjugate vaccines	['serum', 'antibodi', 'concentr', 'capsular', 'polysaccharid', 'haemophilus', 'influenza', 'type', 'prp', 'chilean', 'infant', 'give', 'differ', 'primari', 'immunis', 'regimen', 'prp', 'prp', 'crm', 'conjug', 'vaccin']
83	37447	1.0	0.2812	number, effect, estim, case, women, level, intervent, health, total, region	Estimated odds ratios  (95% CI)  for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children with BHR and relatively low serum total IgE  (n=67)	['estim', 'odd', 'ratio', 'ci', 'preval', 'respiratori', 'symptom', 'decreas', 'peak', 'expiratori', 'flow', 'pef', 'increas', 'air', 'pollut', 'children', 'bhr', 'relat', 'low', 'serum', 'total', 'ige']
84	16262	1.0	0.281	number, effect, estim, case, women, level, intervent, health, total, region	Official development assistance to maternal, newborn, and child health by donor for the 68 Countdown priority countries, 200308	['offici', 'develop', 'assist', 'matern', 'newborn', 'child', 'health', 'donor', 'countdown', 'prioriti', 'countri']
85	35555	1.0	0.2799	number, effect, estim, case, women, level, intervent, health, total, region	Change in numbers of sexual partners and prevalence of sexual practices, behaviours, and attitudes in Natsal-3 and Natsal-1 relative to Natsal-2, by sex	['chang', 'number', 'sexual', 'partner', 'preval', 'sexual', 'practic', 'behaviour', 'attitud', 'natsal', 'natsal', 'relat', 'natsal', 'sex']
86	26766	1.0	0.2791	number, effect, estim, case, women, level, intervent, health, total, region	Birthweights of children born to mothers with chronic pregnancy-associated P falciparum malariaaccording to mothers' plasma IgG concentration with specificity for type of VSA	['birthweight', 'children', 'bear', 'mother', 'chronic', 'pregnanc', 'associ', 'falciparum', 'mother', 'plasma', 'igg', 'concentr', 'specif', 'type', 'vsa']
87	37448	1.0	0.27899999999999997	number, effect, estim, case, women, level, intervent, health, total, region	Estimated odds ratios for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children without BHR but with relatively high serum total IgE  (n=104)	['estim', 'odd', 'ratio', 'preval', 'respiratori', 'symptom', 'decreas', 'peak', 'expiratori', 'flow', 'pef', 'increas', 'air', 'pollut', 'children', 'bhr', 'relat', 'high', 'serum', 'total', 'ige']
88	32236	1.0	0.27899999999999997	number, effect, estim, case, women, level, intervent, health, total, region	AUC of the Different Parameters After the Ingestion of a Phenol-Rich Olive Oil Meal  (400 ppm)  as Compared to a Low Phenol Olive Oil Meal  (80 ppm)	['auc', 'differ', 'paramet', 'ingest', 'phenol', 'rich', 'oliv', 'oil', 'meal', 'ppm', 'compar', 'low', 'phenol', 'oliv', 'oil', 'meal', 'ppm']
89	16219	1.0	0.2782	number, effect, estim, case, women, level, intervent, health, total, region	Estimated preterm birth rates and total number of preterm births for 2010, by Millennium Development Goal region	['estim', 'preterm', 'birth', 'rat', 'total', 'number', 'preterm', 'birth', 'millennium', 'develop', 'goal', 'region']
90	40999	1.0	0.2782	number, effect, estim, case, women, level, intervent, health, total, region	Serum concentrations of antibodies against individual pneumococcal vaccine serotypes and protein D one month after the third protein D conjugate vaccine dose and before and 1 month after booster vaccination*	['serum', 'concentr', 'antibodi', 'individu', 'pneumococc', 'vaccin', 'serotyp', 'protein', 'month', 'protein', 'conjug', 'vaccin', 'dose', 'month', 'booster', 'vaccin']
91	37445	1.0	0.2782	number, effect, estim, case, women, level, intervent, health, total, region	Estimated odds ratios  (95% CI)  for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children with BHR and relatively high serum total IgE  (n=121)	['estim', 'odd', 'ratio', 'ci', 'preval', 'respiratori', 'symptom', 'decreas', 'peak', 'expiratori', 'flow', 'pef', 'increas', 'air', 'pollut', 'children', 'bhr', 'relat', 'high', 'serum', 'total', 'ige']
92	6760	1.0	0.2774	number, effect, estim, case, women, level, intervent, health, total, region	Antibody responses after primary vaccination with PHiD-CV, DTPa-HBV-IPV/Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	['antibodi', 'respons', 'primari', 'vaccin', 'phid', 'cv', 'dtpa', 'hbv', 'ipv', 'hib', 'human', 'rotavirus', 'vaccin', 'prophylact', 'administr', 'paracetamol', 'atp', 'immunogen', 'cohort']
93	13953	1.0	0.2765	number, effect, estim, case, women, level, intervent, health, total, region	Percentage of ever-partnered women reporting selected symptoms of ill health  *   according to experience of physical or sexual violence, or both, by an intimate partner, by site	['percentag', 'partner', 'women', 'report', 'select', 'symptom', 'ill', 'health', 'accord', 'experi', 'physic', 'sexual', 'violenc', 'intim', 'partner', 'site']
94	38080	1.0	0.2765	number, effect, estim, case, women, level, intervent, health, total, region	Median price ratios  *   of originator brands and lowest-priced generics in the private sector, and of lowest-priced generics in the public sector, by WHO Region	['median', 'price', 'ratio', 'origin', 'brand', 'lowest', 'price', 'generic', 'privat', 'sector', 'lowest', 'price', 'generic', 'public', 'sector', 'region']
95	6763	1.0	0.2765	number, effect, estim, case, women, level, intervent, health, total, region	Antibody responses after booster vaccination with PHiD-CV and DTPa-HBV-IPV/Hib with or without prophylactic antipyretic administration  (ATP immunogenicity cohort)	['antibodi', 'respons', 'booster', 'vaccin', 'phid', 'cv', 'dtpa', 'hbv', 'ipv', 'hib', 'prophylact', 'antipyret', 'administr', 'atp', 'immunogen', 'cohort']
96	40305	1.0	0.2752	number, effect, estim, case, women, level, intervent, health, total, region	Comparison of mean adjusted death rate, mean number of acute-care hospital beds, mean number of surgeons, and mean total Medicare-enrollee reimbursements by regions of high, middle, and low adjusted surgical intensity at the end of life	['comparison', 'mean', 'adjust', 'death', 'rate', 'mean', 'number', 'acut', 'care', 'hospit', 'bed', 'mean', 'number', 'surgeon', 'mean', 'total', 'medicar', 'enrolle', 'reimburs', 'region', 'high', 'middl', 'low', 'adjust', 'surgic', 'intens', 'end', 'life']
97	6759	1.0	0.275	number, effect, estim, case, women, level, intervent, health, total, region	OPA responses 1 month after primary vaccination with PHiD-CV, DTPa-HBV-IPV/Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	['opa', 'respons', 'month', 'primari', 'vaccin', 'phid', 'cv', 'dtpa', 'hbv', 'ipv', 'hib', 'human', 'rotavirus', 'vaccin', 'prophylact', 'administr', 'paracetamol', 'atp', 'immunogen', 'cohort']
98	37394	1.0	0.275	number, effect, estim, case, women, level, intervent, health, total, region	Proportion of women with polycystic ovaries, mother's weight, body-mass index, and mean concentrations of plasma LH and testosterone according to birthweight among women whose mothers' weight in pregnancy was above 58 kg  (median)	['proport', 'women', 'polycyst', 'ovari', 'mother', 'weight', 'bodi', 'mass', 'index', 'mean', 'concentr', 'plasma', 'lh', 'testosteron', 'accord', 'birthweight', 'women', 'mother', 'weight', 'pregnanc', 'median']
99	16271	1.0	0.2748	number, effect, estim, case, women, level, intervent, health, total, region	Analysis of association between receipt of financial assistance from Janani Suraksha Yojana and intervention coverage and health outcomes by use of three analytical approaches at the national level	['analysi', 'associ', 'receipt', 'financi', 'assist', 'janani', 'suraksha', 'yojana', 'intervent', 'coverag', 'health', 'outcom', 'use', 'analyt', 'approach', 'nation', 'level']
100	38521	2.0	0.3092	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment efficacy at week 36 for the modified intention-to-treat population in the open-label period and at week 88 for the modified intention-to-treat subpopulations in the double-blind period	['treatment', 'efficaci', 'week', 'modifi', 'intent', 'treat', 'popul', 'open', 'label', 'period', 'week', 'modifi', 'intent', 'treat', 'subpopul', 'doubl', 'blind', 'period']
101	50800	2.0	0.3043	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Overview of treatment-emergent adverse events grade 12  (occurring in 10% of patients) , all grade 3 and worse adverse events, and all serious adverse events	['overview', 'treatment', 'emerg', 'advers', 'event', 'grade', 'occur', 'patient', 'grade', 'wors', 'advers', 'event', 'advers', 'event']
102	45521	2.0	0.3008	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Most common adverse events, grade 3 or worse adverse events, and serious adverse events during the overall treatment period  (neoadjuvant and adjuvant)	['common', 'advers', 'event', 'grade', 'wors', 'advers', 'event', 'advers', 'event', 'overal', 'treatment', 'period', 'neoadjuv', 'adjuv']
103	46196	2.0	0.2978	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Drug-related adverse events occurring at any grade in at least 10% of patients, or at grade 3 or higher in any patients in either group, from the start of treatment to 30 days after the end of treatment  (safety population)	['drug', 'relat', 'advers', 'event', 'occur', 'grade', 'patient', 'grade', 'higher', 'patient', 'group', 'start', 'treatment', 'day', 'end', 'treatment', 'safeti', 'popul']
104	48451	2.0	0.29	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Drug-related treatment-emergent adverse events by MedDRA system organ class and preferred term in the first on-study chemotherapy cycle  (safety population)	['drug', 'relat', 'treatment', 'emerg', 'advers', 'event', 'meddra', 'organ', 'class', 'prefer', 'term', 'studi', 'chemotherapi', 'cycl', 'safeti', 'popul']
105	6454	2.0	0.289	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-emergent adverse events and treatment-emergent drug-related adverse events  *    (safety population)	['treatment', 'emerg', 'advers', 'event', 'treatment', 'emerg', 'drug', 'relat', 'advers', 'event', 'safeti', 'popul']
106	50527	2.0	0.2869	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Adverse events  (any grade)  experienced by 15% or more of patients in either treatment group, and CTCAE grade 3 or higher events occurring in 3% or more of patients in either group	['advers', 'event', 'grade', 'experi', 'patient', 'treatment', 'group', 'ctcae', 'grade', 'higher', 'event', 'occur', 'patient', 'group']
107	33291	2.0	0.2866	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	MedDRA Summary of Treatment Emergent Adverse Events Occurring in >3% in Either Treatment Group by Primary System Organ Class and Preferred Term: All Subjects Population	['meddra', 'summari', 'treatment', 'emerg', 'advers', 'event', 'occur', 'treatment', 'group', 'primari', 'organ', 'class', 'prefer', 'term', 'subject', 'popul']
108	36633	2.0	0.2844	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Safety endpoints and treatment-emergent adverse events of special interest, by treatment assignment over weeks 010  (study part 1)  and weeks 1020  (study part 2)	['safeti', 'endpoint', 'treatment', 'emerg', 'advers', 'event', 'special', 'treatment', 'assign', 'week', 'studi', 'week', 'studi']
109	25628	2.0	0.2836	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-emergent adverse events possibly or probably related to treatment in at least 1% of patients  (intention-to-treat population)	['treatment', 'emerg', 'advers', 'event', 'possibl', 'probabl', 'relat', 'treatment', 'patient', 'intent', 'treat', 'popul']
110	10563	2.0	0.2836	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-emergent adverse events occurring in 10% or more of patients in either group during the double-blind period  (safety population)	['treatment', 'emerg', 'advers', 'event', 'occur', 'patient', 'group', 'doubl', 'blind', 'period', 'safeti', 'popul']
111	37923	2.0	0.2828	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-emergent adverse events in every treatment group during the 12-week treatment period  (safety population)	['treatment', 'emerg', 'advers', 'event', 'treatment', 'group', 'week', 'treatment', 'period', 'safeti', 'popul']
112	45608	2.0	0.2818	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Grade 12 adverse events occurring in 10% or more of patients and all grade 35 adverse events in the fulvestrant plus palbociclib safety population  (all causalities and all cycles)	['grade', 'advers', 'event', 'occur', 'patient', 'grade', 'advers', 'event', 'fulvestr', 'plus', 'palbociclib', 'safeti', 'popul', 'causal', 'cycl']
113	50966	2.0	0.2818	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-emergent adverse events reported by 2% of patients in either treatment group during the double-blind maintenance period	['treatment', 'emerg', 'advers', 'event', 'report', 'patient', 'treatment', 'group', 'doubl', 'blind', 'mainten', 'period']
114	31943	2.0	0.2791	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Overall Incidence of AEs, Discontinuations Due to AEs, and AEs Occurring in 2% of Patients During the Double-Blind Treatment Period  (Safety Population, n = 672)	['overal', 'incid', 'ae', 'ae', 'ae', 'occur', 'patient', 'doubl', 'blind', 'treatment', 'period', 'safeti', 'popul']
115	40231	2.0	0.2782	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Recurrence-free survival, distant metastasis-free survival, and overall survival in the intention-to-treat population	['recurr', 'free', 'surviv', 'distant', 'metastasi', 'free', 'surviv', 'overal', 'surviv', 'intent', 'treat', 'popul']
116	25536	2.0	0.2755	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	All serious adverse events, adverse events occurring in 10% or more of patients in any treatment group, and adverse events of special interest	['advers', 'event', 'advers', 'event', 'occur', 'patient', 'treatment', 'group', 'advers', 'event', 'special']
117	48222	2.0	0.2748	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Most common adverse events leading to everolimus and exemestane discontinuation, dose adjustment, or dose interruption, with suspected relation to everolimus  (safety population, n=92)	['common', 'advers', 'event', 'lead', 'everolimus', 'exemestan', 'discontinu', 'dose', 'adjust', 'dose', 'interrupt', 'suspect', 'relat', 'everolimus', 'safeti', 'popul']
118	47330	2.0	0.2747	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Adverse events  *   of more than 2% difference between treatment groups  (for all grade adverse events)  and adverse events of CTC grade 3  (EFS population)	['advers', 'event', 'differ', 'treatment', 'group', 'grade', 'advers', 'event', 'advers', 'event', 'ctc', 'grade', 'ef', 'popul']
119	25594	2.0	0.2737	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Serious adverse events and most common adverse events related or possibly related to treatment  (ITT population)	['advers', 'event', 'common', 'advers', 'event', 'relat', 'possibl', 'relat', 'treatment', 'itt', 'popul']
120	45343	2.0	0.2711	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-related adverse events of any grade reported in at least 10% of patients and all grade 34 events in 78 patients who received nivolumab	['treatment', 'relat', 'advers', 'event', 'grade', 'report', 'patient', 'grade', 'event', 'patient', 'receiv', 'nivolumab']
121	38128	2.0	0.2693	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-emergent adverse events group in all participants who received 1 dose of study drug  (occurring in 5% in either treatment)	['treatment', 'emerg', 'advers', 'event', 'group', 'particip', 'receiv', 'dose', 'studi', 'drug', 'occur', 'treatment']
122	50419	2.0	0.2685	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-emergent adverse events, irrespective of association with study drug, by preferred term  *   and treatment  (safety set)	['treatment', 'emerg', 'advers', 'event', 'irrespect', 'associ', 'studi', 'drug', 'prefer', 'term', 'treatment', 'safeti', 'set']
123	47541	2.0	0.2685	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Most common adverse events by treatment group, reported by 15% of patients at any grade or by 3% of patients at grade 3 severity  (safety population)   *	['common', 'advers', 'event', 'treatment', 'group', 'report', 'patient', 'grade', 'patient', 'grade', 'sever', 'safeti', 'popul']
124	45555	2.0	0.2685	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Drug-related adverse events  (10% of patients in either treatment group with grade 12 and all grade 3 adverse events; NCI CTCAE 3.0)	['drug', 'relat', 'advers', 'event', 'patient', 'treatment', 'group', 'grade', 'grade', 'advers', 'event', 'nci', 'ctcae']
125	51305	2.0	0.2685	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-related select adverse events and treatment-related adverse events leading to discontinuation of both study drugs	['treatment', 'relat', 'select', 'advers', 'event', 'treatment', 'relat', 'advers', 'event', 'lead', 'discontinu', 'studi', 'drug']
126	6337	2.0	0.2675	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Summary of total adverse events and treatment-related adverse events through week 96 in the safety maintenance population	['summari', 'total', 'advers', 'event', 'treatment', 'relat', 'advers', 'event', 'week', 'safeti', 'mainten', 'popul']
127	50386	2.0	0.2671	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Grade 3 or 4 and serious adverse events and reactions, and adverse events leading to quinacrine discontinuation or dose reduction	['grade', 'advers', 'event', 'reaction', 'advers', 'event', 'lead', 'quinacrin', 'discontinu', 'dose', 'reduct']
128	46849	2.0	0.2657	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Overall survival in all randomly allocated patients who received at least one dose of study treatment in the intention-to-treat population	['overal', 'surviv', 'random', 'alloc', 'patient', 'receiv', 'dose', 'studi', 'treatment', 'intent', 'treat', 'popul']
129	46268	2.0	0.2653	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Adverse events reported by 10% or more patients for grades 1 and 2 and all adverse events for grades 35  (safety population)	['advers', 'event', 'report', 'patient', 'grade', 'advers', 'event', 'grade', 'safeti', 'popul']
130	46088	2.0	0.265	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Adverse events of 10% incidence in either treatment group or grade 3, 4 adverse events of 05% incidence in either treatment group  (safety set)	['advers', 'event', 'incid', 'treatment', 'group', 'grade', 'advers', 'event', 'incid', 'treatment', 'group', 'safeti', 'set']
131	46091	2.0	0.2646	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Drug-related adverse events  (10% of patients in either treatment group with grade 12 and all grade 3 adverse events) .	['drug', 'relat', 'advers', 'event', 'patient', 'treatment', 'group', 'grade', 'grade', 'advers', 'event']
132	12853	2.0	0.2643	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Grade 3 and 4 adverse events  *   experienced by 2% or more of patients and adverse events leading to treatment discontinuation, after randomisation to rituximab maintenance or observation	['grade', 'advers', 'event', 'experi', 'patient', 'advers', 'event', 'lead', 'treatment', 'discontinu', 'randomis', 'rituximab', 'mainten', 'observ']
133	46173	2.0	0.2639	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Common adverse events  (10% in either treatment group)  reported up to 28 days after study drug discontinuation  (safety population)	['common', 'advers', 'event', 'treatment', 'group', 'report', 'day', 'studi', 'drug', 'discontinu', 'safeti', 'popul']
134	13214	2.0	0.2639	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-emergent adverse events  (MedDRA HLT or PT)  occurring in 5% or more of patients in the placebo or combined dupilumab doses groups  *	['treatment', 'emerg', 'advers', 'event', 'meddra', 'hlt', 'pt', 'occur', 'patient', 'placebo', 'combin', 'dupilumab', 'dose', 'group']
135	40804	2.0	0.2621	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Overview of incidence of treatment-emergent adverse events by treatment at adverse event onset by system organ class	['overview', 'incid', 'treatment', 'emerg', 'advers', 'event', 'treatment', 'advers', 'event', 'onset', 'organ', 'class']
136	39071	2.0	0.2621	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Overall incidence of treatment-emergent adverse events occurring in 10% or more of patients who received one or more doses of study drug	['overal', 'incid', 'treatment', 'emerg', 'advers', 'event', 'occur', 'patient', 'receiv', 'dose', 'studi', 'drug']
137	46331	2.0	0.262	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Overview of adverse events, classified by Common Terminology Criteria for Adverse Events  (version 3.0)  in all patients who received at least one dose of study drug	['overview', 'advers', 'event', 'classifi', 'common', 'terminolog', 'criteria', 'advers', 'event', 'version', 'patient', 'receiv', 'dose', 'studi', 'drug']
138	47132	2.0	0.2618	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Incidence of grade 35 adverse events occurring in 2% or more of patients given chemotherapy with or without bevacizumab after disease progression following first-line bevacizumab-based treatment  (safety population  *  )	['incid', 'grade', 'advers', 'event', 'occur', 'patient', 'give', 'chemotherapi', 'bevacizumab', 'diseas', 'progress', 'follow', 'line', 'bevacizumab', 'base', 'treatment', 'safeti', 'popul']
139	25629	2.0	0.2616	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-emergent adverse events leading to discontinuation of treatment  (intention-to-treat population)	['treatment', 'emerg', 'advers', 'event', 'lead', 'discontinu', 'treatment', 'intent', 'treat', 'popul']
140	10624	2.0	0.2609	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Virological response over time  (RVR and SVR12) , and on-treatment failure and relapse, according to treatment group in the intention-to-treat population	['virolog', 'respons', 'time', 'rvr', 'svr', 'treatment', 'failur', 'relaps', 'accord', 'treatment', 'group', 'intent', 'treat', 'popul']
141	46370	2.0	0.2609	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Most common  (10%)  treatment-emergent adverse events by study group and preferred term  (safety population)	['common', 'treatment', 'emerg', 'advers', 'event', 'studi', 'group', 'prefer', 'term', 'safeti', 'popul']
142	40452	2.0	0.2597	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Overview of treatment-emergent adverse events  (MedDRA preferred terms)  and injection-site reactions  (MeDRA high-level terms)  in the safety population	['overview', 'treatment', 'emerg', 'advers', 'event', 'meddra', 'prefer', 'term', 'inject', 'site', 'reaction', 'medra', 'high', 'level', 'term', 'safeti', 'popul']
143	25551	2.0	0.2597	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-emergent adverse events leading to discontinuation of study drug in the safety population  (n=2485)	['treatment', 'emerg', 'advers', 'event', 'lead', 'discontinu', 'studi', 'drug', 'safeti', 'popul']
144	25913	2.0	0.2591	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Patients with any adverse event and with grade 34 adverse events related to study treatment  (2-weekly regimen)	['patient', 'advers', 'event', 'grade', 'advers', 'event', 'relat', 'studi', 'treatment', 'week', 'regimen']
145	47430	2.0	0.2579	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Incidence of prespecified treatment-emergent adverse events  (preferred terms)  during the double-blind period  (safety population, n=515)	['incid', 'prespecifi', 'treatment', 'emerg', 'advers', 'event', 'prefer', 'term', 'doubl', 'blind', 'period', 'safeti', 'popul']
146	6655	2.0	0.2579	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Serious adverse events in any treatment group and treatment-emergent adverse events occurring in 5% or more of patients	['advers', 'event', 'treatment', 'group', 'treatment', 'emerg', 'advers', 'event', 'occur', 'patient']
147	6324	2.0	0.2579	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-emergent adverse events of any grade reported in at least 10% of patients in either group in the safety population	['treatment', 'emerg', 'advers', 'event', 'grade', 'report', 'patient', 'group', 'safeti', 'popul']
148	39308	2.0	0.2576	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Proportion of participants experiencing at least one grade 35 adverse event by 52 weeks that was possibly, probably, or definitely related to study treatment using a modified intention-to-treat analysis for a model based on the raw dataset and imputed dataset	['proport', 'particip', 'experi', 'grade', 'advers', 'event', 'week', 'possibl', 'probabl', 'definit', 'relat', 'studi', 'treatment', 'modifi', 'intent', 'treat', 'analysi', 'model', 'base', 'raw', 'dataset', 'imput', 'dataset']
149	10707	2.0	0.2574	event, treatment, advers, group, popul, patient, studi, surviv, respons, treat	Treatment-related adverse events occurring in 5% of patients in either group from start of treatment to 30 days after end of treatment  (safety population)   *	['treatment', 'relat', 'advers', 'event', 'occur', 'patient', 'group', 'start', 'treatment', 'day', 'end', 'treatment', 'safeti', 'popul']
150	23993	3.0	0.3514	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Early Clopidogrel and Glycoprotein IIb/IIIa Inhibitor Use in Patients Managed With Early Invasive Strategy  (Cath 48 h From Admission)  Versus Conservative Care  (Cath >48 h After Admission or No Cath)	['earli', 'clopidogrel', 'glycoprotein', 'iib', 'iiia', 'inhibitor', 'use', 'patient', 'manag', 'earli', 'invas', 'strategi', 'cath', 'admiss', 'versus', 'conserv', 'care', 'cath', 'admiss', 'cath']
151	24738	3.0	0.2903	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Patients With Standardized Criteria for Urgent and Elective Coronary Angiogram, and Rates of Urgent PTCA and CABG Among These Patients During the 28 Days Following Onset of Unstable Angina, by Type of Hospital	['patient', 'standard', 'criteria', 'urgent', 'elect', 'coronari', 'angiogram', 'rat', 'urgent', 'ptca', 'cabg', 'patient', 'day', 'follow', 'onset', 'unstabl', 'angina', 'type', 'hospit']
152	16871	3.0	0.2859	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Procedures, Complications and Clinical Outcomes of Patients at Hospital Discharge in Invasive and Conservative Therapy Groups Following Matching by Propensity Analysis	['procedur', 'complic', 'clinic', 'outcom', 'patient', 'hospit', 'discharg', 'invas', 'conserv', 'therapi', 'group', 'follow', 'match', 'propens', 'analysi']
153	9231	3.0	0.2782	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	A Summary of Time Frames of PTCA, Surgery, Antiplatelet Therapy and Complications in Patients Who Experienced Major Complications After Noncardiac Surgery Preceded by Intracoronary Stent Placement legend	['summari', 'time', 'frame', 'ptca', 'surgeri', 'antiplatelet', 'therapi', 'complic', 'patient', 'experi', 'major', 'complic', 'noncardiac', 'surgeri', 'preced', 'intracoronari', 'stent', 'placement']
154	16362	3.0	0.2684	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Effect of Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle on Cardiac Electrophysiologic Parameters in Postinfarction Dogs legend	['effect', 'intraven', 'losartan', 'mg', 'mg', 'min', 'exp', 'mg', 'mg', 'min', 'captopril', 'mg', 'mg', 'vehicl', 'cardiac', 'paramet', 'postinfarct', 'dog']
155	16363	3.0	0.2645	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Plasma Renin Activities in Postinfarction Dogs Administered Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle legend	['plasma', 'renin', 'activ', 'postinfarct', 'dog', 'administ', 'intraven', 'losartan', 'mg', 'mg', 'min', 'exp', 'mg', 'mg', 'min', 'captopril', 'mg', 'mg', 'vehicl']
156	16364	3.0	0.263	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Effect of Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle on the Incidence of Lethal Ischemic Arrhythmias Developing in Response to Secondary Acute Posterolateral Myocardial Ischemia in Postinfarction Dogs	['effect', 'intraven', 'losartan', 'mg', 'mg', 'min', 'exp', 'mg', 'mg', 'min', 'captopril', 'mg', 'mg', 'vehicl', 'incid', 'lethal', 'ischem', 'arrhythmia', 'develop', 'respons', 'secondari', 'acut', 'posterolater', 'myocardi', 'ischemia', 'postinfarct', 'dog']
157	42087	3.0	0.2575	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Initial Procedural Outcome  (Among 608 CABG and PTCA Patients With IR Intended and 579 PTCA Patients With CR Intended if Randomized to PTCA Who Received Their Assigned Treatment)  legend	['initi', 'procedur', 'outcom', 'cabg', 'ptca', 'patient', 'ir', 'intend', 'ptca', 'patient', 'cr', 'intend', 'random', 'ptca', 'receiv', 'assign', 'treatment']
158	32023	3.0	0.2568	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Ischemic and Bleeding Outcomes 12 to 30 Months After Coronary Stent Treatment in all Randomized Patients, Stratified by Presentation With Versus Without Acute Myocardial Infarction	['ischem', 'bleed', 'outcom', 'month', 'coronari', 'stent', 'treatment', 'random', 'patient', 'stratifi', 'present', 'versus', 'acut', 'myocardi', 'infarct']
159	9006	3.0	0.2558	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Death, MI, or Refractory Ischemia or Major Bleeding in Patients Undergoing PCI by Loading Dose of Clopidogrel or Type of GP IIb/IIIa Inhibitor	['death', 'mi', 'refractori', 'ischemia', 'major', 'bleed', 'patient', 'undergo', 'pci', 'load', 'dose', 'clopidogrel', 'type', 'gp', 'iib', 'iiia', 'inhibitor']
160	16869	3.0	0.2555	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Procedures, Complications and Clinical Outcomes of Patients at Hospital Discharge in Invasive and Conservative Therapy Groups *	['procedur', 'complic', 'clinic', 'outcom', 'patient', 'hospit', 'discharg', 'invas', 'conserv', 'therapi', 'group']
161	16361	3.0	0.2535	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Effect of Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle on Sinus Heart Rate, Mean Arterial Pressure and Electrocardiographic Intervals in Postinfarction Dogs legend	['effect', 'intraven', 'losartan', 'mg', 'mg', 'min', 'exp', 'mg', 'mg', 'min', 'captopril', 'mg', 'mg', 'vehicl', 'sinus', 'heart', 'rate', 'mean', 'arteri', 'pressur', 'interv', 'postinfarct', 'dog']
162	5661	3.0	0.2518	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Intraoperative and Postoperative Complications for Patients Undergoing Off-Pump and On-Pump CABG Surgery in New York State, 19972000	['intraop', 'postop', 'complic', 'patient', 'undergo', 'pump', 'pump', 'cabg', 'surgeri', 'new', 'york', 'state']
163	19494	3.0	0.2466	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Risk of THV Thrombosis in Relation to Post-TAVR Antithrombotic Therapy Until 1- to 3-Month Post-TAVR Follow-Up  (Routine Follow-Up Visit 1)	['risk', 'thv', 'thrombosi', 'relat', 'post', 'tavr', 'antithrombot', 'therapi', 'month', 'post', 'tavr', 'follow', 'routin', 'follow', 'visit']
164	9005	3.0	0.2466	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Death, MI, Refractory Ischemia, Major Bleeding, and Net Clinical Outcome at 30 Days in Those Treated With a GP IIb/IIIa Inhibitor	['death', 'mi', 'refractori', 'ischemia', 'major', 'bleed', 'net', 'clinic', 'outcom', 'day', 'treat', 'gp', 'iib', 'iiia', 'inhibitor']
165	30747	3.0	0.2464	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	In-Hospital Course of Patients With Acute Myocardial Infarction and Cardiogenic Shock Treated With or Without Intraaortic Balloon Counterpulsation	['hospit', 'cours', 'patient', 'acut', 'myocardi', 'infarct', 'cardiogen', 'shock', 'treat', 'intraaort', 'balloon']
166	37578	3.0	0.2449	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Sensitivity analysis and 1-year mortality in all patients and in patients who survived until day 14, day 30, day 60, and day 90 after acute myocardial infarction  (AMI)	['sensit', 'analysi', 'year', 'mortal', 'patient', 'patient', 'surviv', 'day', 'day', 'day', 'day', 'acut', 'myocardi', 'infarct', 'ami']
167	33676	3.0	0.2442	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Mortality Over Time Among All Patients in PCI Studies Randomizing Patients to Standard Therapy or Standard Therapy Plus Abciximab With a 12-h Infusion After PCI  (Excludes Patients Not Randomized to a Common Intervention [EPISTENT PTCA/Abciximab Group])  legend	['mortal', 'time', 'patient', 'pci', 'studi', 'random', 'patient', 'standard', 'therapi', 'standard', 'therapi', 'plus', 'abciximab', 'infus', 'pci', 'exclud', 'patient', 'random', 'common', 'intervent', 'epist', 'ptca', 'abciximab', 'group']
168	30748	3.0	0.2442	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Community Hospital Complications of Patients With Acute Myocardial Infarction and Cardiogenic Shock Treated With or Without Intraaortic Balloon Counterpulsation	['communiti', 'hospit', 'complic', 'patient', 'acut', 'myocardi', 'infarct', 'cardiogen', 'shock', 'treat', 'intraaort', 'balloon']
169	50710	3.0	0.2435	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Neurological presentations of 424 patients with gluten sensitivity, who presented with neurological dysfunction and were seen in the gluten sensitivity/neurology clinic, in Sheffield, UK, from 1994 to 2009	['neurolog', 'present', 'patient', 'gluten', 'sensit', 'present', 'neurolog', 'dysfunct', 'see', 'gluten', 'sensit', 'neurolog', 'clinic', 'sheffield', 'uk']
170	18715	3.0	0.2427	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Revascularization Procedures in Post-Lytic NQMI Patients Randomized to Invasive  (INV)  or Conservative  (CON)  Management Strategies legend	['procedur', 'post', 'lytic', 'nqmi', 'patient', 'random', 'invas', 'inv', 'conserv', 'manag', 'strategi']
171	4720	3.0	0.2424	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Early and Late Outcomes of Hospital Survivors of AMI and Cardiogenic Shock According To Myocardial Infarction Type	['earli', 'late', 'outcom', 'hospit', 'survivor', 'ami', 'cardiogen', 'shock', 'accord', 'myocardi', 'infarct', 'type']
172	30697	3.0	0.2409	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	In-Hospital Outcomes of Elderly Patients  (65 years old)  With or Without Previous Angina 48 Hours Before Acute Myocardial Infarction	['hospit', 'outcom', 'elder', 'patient', 'year', 'old', 'previous', 'angina', 'hour', 'acut', 'myocardi', 'infarct']
173	21442	3.0	0.2409	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Clinical Outcomes at 30 Days According to Consistent Therapy on Enoxaparin Versus Switch From Enoxaparin to Bivalirudin	['clinic', 'outcom', 'day', 'accord', 'consist', 'therapi', 'enoxaparin', 'versus', 'switch', 'enoxaparin', 'bivalirudin']
174	23975	3.0	0.2403	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Clinical Outcomes Stratified by Stent Type and Peri-Procedure Administration of Platelet Glycoprotein IIb/IIIa Inhibitors	['clinic', 'outcom', 'stratifi', 'stent', 'type', 'peri', 'procedur', 'administr', 'platelet', 'glycoprotein', 'iib', 'iiia', 'inhibitor']
175	32534	3.0	0.2385	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	In-Hospital Bleeding Complications of Patients With ST Segment Elevation Myocardial Infarction According to Thrombolytic and Antithrombin Therapy	['hospit', 'bleed', 'complic', 'patient', 'st', 'segment', 'elev', 'myocardi', 'infarct', 'accord', 'thrombolyt', 'antithrombin', 'therapi']
176	16921	3.0	0.2376	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Comparison of Admitting Diagnosis and Initial Hospital Bed Assignments of 29,585 Patients With LBBB and Acute MI in the National Registry for Myocardial Infarction 2  (June 1, 1994March 31, 1998)  legend	['comparison', 'admit', 'diagnosi', 'initi', 'hospit', 'bed', 'assign', 'patient', 'lbbb', 'acut', 'mi', 'nation', 'registri', 'myocardi', 'infarct', 'june', 'march']
177	17444	3.0	0.2365	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	30-Day and Long-Term Reinfarction According to Degree of ST-Segment Resolution at 90 Min and 4 Hours After Initiation of Reperfusion Therapy	['day', 'long', 'term', 'reinfarct', 'accord', 'degre', 'st', 'segment', 'resolut', 'min', 'hour', 'initi', 'reperfus', 'therapi']
178	16922	3.0	0.2363	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Comparison of Treatments Received by 29,585 Patients With Acute MI and LBBB With and Without Chest Pain in the National Registry for Myocardial Infarction 2  (June 1, 1994March 31, 1998)  legend legend	['comparison', 'treatment', 'receiv', 'patient', 'acut', 'mi', 'lbbb', 'chest', 'pain', 'nation', 'registri', 'myocardi', 'infarct', 'june', 'march']
179	17790	3.0	0.2361	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Clinical Outcomes at Day 9 in Patients Undergoing Early PCI  (Within 24 h of Randomization)	['clinic', 'outcom', 'day', 'patient', 'undergo', 'earli', 'pci', 'random']
180	32528	3.0	0.235	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Serial Electrocardiographic Changes in Patients With Suspected Acute Myocardial Infarction Who Were Not Receive Randomized to Prehospital Versus In-Hospital Thrombolysis	['serial', 'chang', 'patient', 'suspect', 'acut', 'myocardi', 'infarct', 'receiv', 'random', 'prehospit', 'versus', 'hospit', 'thrombolysi']
181	32535	3.0	0.2332	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Clinical Outcomes at 30 Days in Patients With ST Segment Elevation Myocardial Infarction According to Thrombolytic and Antithrombin Therapy	['clinic', 'outcom', 'day', 'patient', 'st', 'segment', 'elev', 'myocardi', 'infarct', 'accord', 'thrombolyt', 'antithrombin', 'therapi']
182	4865	3.0	0.2331	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With>12 Months Versus12Months of Clopidogrel After IndexPercutaneous Coronary Revascularization With BMS	['landmark', 'analysi', 'risk', 'clinic', 'endpoint', 'patient', 'dm', 'treat', 'month', 'versus', 'month', 'clopidogrel', 'coronari', 'bms']
183	30699	3.0	0.2325	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Protective Role of Angina 48 Hours Before Acute Myocardial Infarction in Adult and Elderly Patients: Adjusted Regression Model for In-Hospital Death and Congestive Heart Failure or Shock and Combined End Points  (in-hospital death, congestive heart failure or shock)   a	['protect', 'role', 'angina', 'hour', 'acut', 'myocardi', 'infarct', 'adult', 'elder', 'patient', 'adjust', 'regress', 'model', 'hospit', 'death', 'congest', 'heart', 'failur', 'shock', 'combin', 'end', 'point', 'hospit', 'death', 'congest', 'heart', 'failur', 'shock']
184	30698	3.0	0.2325	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Protective Role of Angina 48 Hours Before Acute Myocardial Infarction in Adult and Elderly Patients: Unadjusted Regression Model for In-Hospital Death and Congestive Heart Failure or Shock and Combined End Points  (in-hospital death, congestive heart failure or shock)	['protect', 'role', 'angina', 'hour', 'acut', 'myocardi', 'infarct', 'adult', 'elder', 'patient', 'unadjust', 'regress', 'model', 'hospit', 'death', 'congest', 'heart', 'failur', 'shock', 'combin', 'end', 'point', 'hospit', 'death', 'congest', 'heart', 'failur', 'shock']
185	19277	3.0	0.2319	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	In-Hospital Clinical Outcomes of Patients Undergoing Isolated Tricuspid Valve Surgery From 2004 to 2013  (Unweighted)	['hospit', 'clinic', 'outcom', 'patient', 'undergo', 'isol', 'tricuspid', 'valv', 'surgeri', 'unweight']
186	17788	3.0	0.2319	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Short-Term and Long-Term Major Adverse Clinical Events in PCI Patients	['short', 'term', 'long', 'term', 'major', 'advers', 'clinic', 'event', 'pci', 'patient']
187	17897	3.0	0.2316	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Early and Systematic Versus Guided or Delayed PCI  (Stent Era and Balloon Era)  After Fibrinolysis for STEMI	['earli', 'systemat', 'versus', 'guid', 'delay', 'pci', 'stent', 'era', 'balloon', 'era', 'fibrinolysi', 'stemi']
188	25013	3.0	0.2313	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Effect of Surgery on Exercise Parameters in Patients Undergoing Mitral Valve Replacement and Patients Undergoing Mitral Valve Repair legend	['effect', 'surgeri', 'exercis', 'paramet', 'patient', 'undergo', 'mitral', 'valv', 'replac', 'patient', 'undergo', 'mitral', 'valv', 'repair']
189	32235	3.0	0.2313	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Individual Event Rates  (Event/Month)  and Therapy Episodes  (Episode/Month)  of Patients Pre- and Post-CRT Implantation	['individu', 'event', 'rat', 'event', 'month', 'therapi', 'episod', 'episod', 'month', 'patient', 'pre', 'post', 'crt', 'implant']
190	5690	3.0	0.2305	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Complications of Thrombolytic Therapy of Prosthetic Valve Thrombosis in 107 Patients	['complic', 'thrombolyt', 'therapi', 'prosthet', 'valv', 'thrombosi', 'patient']
191	32587	3.0	0.2302	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Clinical Outcomes in Surgically and Nonsurgically Treated Patients After Acute Myocardial Infarction	['clinic', 'outcom', 'surgic', 'nonsurg', 'treat', 'patient', 'acut', 'myocardi', 'infarct']
192	37874	3.0	0.2301	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Effects of aspirin on bleeding episodes and related complications in elective-arthroplasty patients up to day 35	['effect', 'aspirin', 'bleed', 'episod', 'relat', 'complic', 'elect', 'arthroplasti', 'patient', 'day']
193	18126	3.0	0.2301	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Hierarchical Incidence of MACE During Hospitalization and 12-Month Follow-Up in Patients With Successful Recanalization of a CTO	['hierarch', 'incid', 'mace', 'hospit', 'month', 'follow', 'patient', 'success', 'recan', 'cto']
194	25706	3.0	0.23	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	1-Year Clinical Outcomes in Patients With In-Hospital Versus Out-of-Hospital Definite/Probable Stent Thrombosis	['year', 'clinic', 'outcom', 'patient', 'hospit', 'versus', 'hospit', 'definit', 'probabl', 'stent', 'thrombosi']
195	27968	3.0	0.2298	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	30-Day and 1-Year Event Rates According to the Occurrence of Major VC Versus No Major VC Up to 30 Days	['day', 'year', 'event', 'rat', 'accord', 'occurr', 'major', 'vc', 'versus', 'major', 'vc', 'day']
196	44166	3.0	0.2298	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	In-Hospital Invasive Coronary Procedures, Medications, Complications and Mortality of Patients Treated or Not Treated by Acute Reperfusion legend	['hospit', 'invas', 'coronari', 'procedur', 'medic', 'complic', 'mortal', 'patient', 'treat', 'treat', 'acut', 'reperfus']
197	32022	3.0	0.2296	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Ischemic and Bleeding Outcomes in all Randomized Patients, According to Acute Myocardial Infarction Status, From12 to 30 Months After Coronary Stent Treatment	['ischem', 'bleed', 'outcom', 'random', 'patient', 'accord', 'acut', 'myocardi', 'infarct', 'status', 'month', 'coronari', 'stent', 'treatment']
198	18716	3.0	0.2295	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Reported Cause of Death and Procedures Performed in Post-Lytic NQMI Patients Randomized to Invasive  (INV)  and Conservative  (CON)  Management Strategies legend	['report', 'caus', 'death', 'procedur', 'perform', 'post', 'lytic', 'nqmi', 'patient', 'random', 'invas', 'inv', 'conserv', 'manag', 'strategi']
199	28899	3.0	0.2291	patient, clinic, outcom, follow, month, day, hospit, procedur, myocardi, therapi	Study Endpoints in Matched Patients: Admission Rate, Length of Stay, MACE, Additional Patient Follow-Up, and Downstream Resource Utilization With CCTA Versus Standard Evaluation  (Both, n= 894)	['studi', 'endpoint', 'match', 'patient', 'admiss', 'rate', 'length', 'stay', 'mace', 'addit', 'patient', 'follow', 'downstream', 'resourc', 'util', 'ccta', 'versus', 'standard', 'evalu']
200	48105	4.0	0.3294	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	5-year relative survival  (%)  by use of state-specific and race-specific life tables and age-standardised to ICSS weights  *   with 95% CIs     for adults  (aged 1599 years)  diagnosed with cancer of the breast  (women) , colon, rectum, or prostate during 199094 and followed up to Dec 31, 1999, by ra US populations	['year', 'relat', 'surviv', 'use', 'state', 'specif', 'race', 'specif', 'life', 'tabl', 'age', 'standardis', 'icss', 'weight', 'cis', 'adult', 'age', 'year', 'diagnos', 'cancer', 'breast', 'women', 'colon', 'rectum', 'prostat', 'follow', 'dec', 'ra', 'popul']
201	10763	4.0	0.3237	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Decomposition analysis of the change of global disability-adjusted life years  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific disability-adjusted-life-year rates	['decomposit', 'analysi', 'chang', 'global', 'disabl', 'adjust', 'life', 'year', 'thousand', 'level', 'caus', 'total', 'popul', 'growth', 'popul', 'age', 'chang', 'age', 'specif', 'sex', 'specif', 'caus', 'specif', 'disabl', 'adjust', 'life', 'year', 'rat']
202	15998	4.0	0.3229	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Global all-age attributable deaths and DALYs, in 2006 and 2016, and percentage change of deaths, age-standardised death rates, DALYs, and age-standardised DALY rates between 2006 and 2016, for all risk-outcome pairs, both sexes combined	['global', 'age', 'attribut', 'death', 'dali', 'percentag', 'chang', 'death', 'age', 'standardis', 'death', 'rat', 'dali', 'age', 'standardis', 'dali', 'rat', 'risk', 'outcom', 'pair', 'sex', 'combin']
203	27413	4.0	0.3228	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	40-year trends in the index of net survival for all cancers combined at 1, 5, and 10 years after diagnosis in adults  (1599 years)  in England from 1971 to 2011 and trends in the age-adjusted net survival for 21 selected cancers in England from 1971 to 2011 by sex	['year', 'trend', 'index', 'net', 'surviv', 'cancer', 'combin', 'year', 'diagnosi', 'adult', 'year', 'england', 'trend', 'age', 'adjust', 'net', 'surviv', 'select', 'cancer', 'england', 'sex']
204	13352	4.0	0.3219	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Age-standardised 5-year net survival  (%)  with 95% CI: adults  (1599 years)  diagnosed with one of eight common malignancies  (oesophagus, stomach, colon, rectum, liver, pancreas, lung, or melanoma of the skin)  by continent, country, and calendar period of diagnosis	['age', 'standardis', 'year', 'net', 'surviv', 'ci', 'adult', 'year', 'diagnos', 'common', 'malign', 'oesophagus', 'stomach', 'colon', 'rectum', 'liver', 'pancrea', 'lung', 'melanoma', 'skin', 'contin', 'countri', 'calendar', 'period', 'diagnosi']
205	27414	4.0	0.3212	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	40-year trends in the index of net survival for all cancers combined at 1, 5, and 10 years after diagnosis in adults  (1599 years)  in Wales from 1971 to 2011 and trends in the age-adjusted net survival for 21 selected cancers in Wales from 1971 to 2011 by sex	['year', 'trend', 'index', 'net', 'surviv', 'cancer', 'combin', 'year', 'diagnosi', 'adult', 'year', 'wale', 'trend', 'age', 'adjust', 'net', 'surviv', 'select', 'cancer', 'wale', 'sex']
206	48104	4.0	0.3154	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	5-year relative survival  (%) , age-standardised to ICSS weights  *   with 95% CIs for adults  (aged 1599 years)  diagnosed with cancer of the breast  (women) , colon, rectum, or prostate during 199094 and followed up to Dec 31, 1999: continent, country, and region	['year', 'relat', 'surviv', 'age', 'standardis', 'icss', 'weight', 'cis', 'adult', 'age', 'year', 'diagnos', 'cancer', 'breast', 'women', 'colon', 'rectum', 'prostat', 'follow', 'dec', 'contin', 'countri', 'region']
207	15389	4.0	0.3142	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Age-adjusted annual incidence and mortality rates  (per 100000 person-years) , disability-adjusted life-years  (DALYs)  lost, prevalence  (per 100000 people) , and mortality-to-incidence ratio  (MIR)  by age groups in high-income and low-income and middle-income countries, and globally in 1990, 2005, and 2010	['age', 'adjust', 'annual', 'incid', 'mortal', 'rat', 'person', 'year', 'disabl', 'adjust', 'life', 'year', 'dali', 'lose', 'preval', 'peopl', 'mortal', 'incid', 'ratio', 'mir', 'age', 'group', 'high', 'incom', 'low', 'incom', 'middl', 'incom', 'countri', 'global']
208	37567	4.0	0.2962	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Observed  (obs)  number of sibling pairs with cancer and standardised incidence ratios  (SIR)  in siblings of children with cancer, followed-up in childhood and adolescence, stratified by type of cancer of index patient	['observ', 'ob', 'number', 'sibl', 'pair', 'cancer', 'standardis', 'incid', 'ratio', 'sir', 'sibl', 'children', 'cancer', 'follow', 'childhood', 'adolesc', 'stratifi', 'type', 'cancer', 'index', 'patient']
209	39432	4.0	0.2962	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Male dose-related excess mortality in ever-drinkers as a proportion of all mortality in male ever-drinkers and never-drinkers, by age and underlying cause of death	['male', 'dose', 'relat', 'excess', 'mortal', 'drinker', 'proport', 'mortal', 'male', 'drinker', 'drinker', 'age', 'underli', 'caus', 'death']
210	39433	4.0	0.2944	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Female dose-related excess mortality in ever-drinkers as a proportion of all mortality in female ever-drinkers and never-drinkers, by age and underlying cause of death	['femal', 'dose', 'relat', 'excess', 'mortal', 'drinker', 'proport', 'mortal', 'femal', 'drinker', 'drinker', 'age', 'underli', 'caus', 'death']
211	12120	4.0	0.2944	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Top 10 causes of disability-adjusted life-years  (DALYs)  in males, females, and both for ages 1014 years, 1519 years, and 2024 years, 1990, 2005, and 2013	['caus', 'disabl', 'adjust', 'life', 'year', 'dali', 'male', 'femal', 'age', 'year', 'year', 'year']
212	13800	4.0	0.293	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Age-standardised and sex-standardised mortality ratios of all-cause, suicide-related, and cancer-related mortality in patients with chronic fatigue syndrome, compared with the general population in England and Wales in 2011	['age', 'standardis', 'sex', 'standardis', 'mortal', 'ratio', 'caus', 'suicid', 'relat', 'cancer', 'relat', 'mortal', 'patient', 'chronic', 'fatigu', 'syndrom', 'compar', 'general', 'popul', 'england', 'wale']
213	16488	4.0	0.2925	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	5-year age-standardised net survival for adults  (aged 1599 years)  diagnosed with one of ten common malignant diseases and children  (aged 014 years)  with ALL, by continent, country, and calendar period of diagnosis	['year', 'age', 'standardis', 'net', 'surviv', 'adult', 'age', 'year', 'diagnos', 'common', 'malign', 'diseas', 'children', 'age', 'year', 'contin', 'countri', 'calendar', 'period', 'diagnosi']
214	6484	4.0	0.29	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Global life expectancy at birth and at age 50, age-standardised death rates, age-standardised YLL rate, and total deaths, by sex, 19802015	['global', 'life', 'expect', 'birth', 'age', 'age', 'standardis', 'death', 'rat', 'age', 'standardis', 'yll', 'rate', 'total', 'death', 'sex']
215	25467	4.0	0.2877	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Observed and expected deaths from breast cancer in the initial cohort within 16 years and rate ratios  (intervention centres vs combined comparison centres)  for cases diagnosed within 7 and 10 years of date of entry	['observ', 'expect', 'death', 'breast', 'cancer', 'initi', 'cohort', 'year', 'rate', 'ratio', 'intervent', 'centr', 'vs', 'combin', 'comparison', 'centr', 'case', 'diagnos', 'year', 'date', 'entri']
216	44808	4.0	0.2872	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Life years lost and excess life years lost by cause of death in people with and without mental disorders	['life', 'year', 'lose', 'excess', 'life', 'year', 'lose', 'caus', 'death', 'peopl', 'mental', 'disord']
217	49468	4.0	0.2866	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Adjusted hazard ratios  (HRs)  for mortality in relation to childhood BMI and BMI change during puberty for 37672 Swedish men followed for a mean of 378 years after age 20 years	['adjust', 'hazard', 'ratio', 'hrs', 'mortal', 'relat', 'childhood', 'bmi', 'bmi', 'chang', 'puberti', 'swedish', 'men', 'follow', 'mean', 'year', 'age', 'year']
218	47978	4.0	0.2859	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Standardised incidence ratios  (SIRs)  for nervous-system tumour types subdivided by age at diagnosis in offspring with a sibling diagnosed with any nervous-system tumour	['standardis', 'incid', 'ratio', 'sir', 'nervous', 'tumour', 'type', 'subdivid', 'age', 'diagnosi', 'offspr', 'sibl', 'diagnos', 'nervous', 'tumour']
219	39430	4.0	0.2845	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Male relative risk of death at ages 1574 years, by proxy-reported alcohol intake  (other drinkers vs reference drinkers, excluding never-drinkers)  and certified cause  (other causes vs control diseases)	['male', 'relat', 'risk', 'death', 'age', 'year', 'proxi', 'report', 'alcohol', 'intak', 'drinker', 'vs', 'refer', 'drinker', 'exclud', 'drinker', 'certifi', 'caus', 'caus', 'vs', 'control', 'diseas']
220	32718	4.0	0.2843	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Unadjusted and Adjusted Association of Heart Rate Variability Variables With All-Cause Mortality, Cardiac Mortality, Sudden Cardiac Mortality, Sudden Cardiac Autopsy-Verified Mortality, Sudden Cardiac Mortality for Both Genders, Nonsudden Cardiac Mortality and Nonsudden Cardiac Mortality With Cerebrovascular Mortality legend legend	['unadjust', 'adjust', 'associ', 'heart', 'rate', 'variabl', 'variabl', 'caus', 'mortal', 'cardiac', 'mortal', 'sudden', 'cardiac', 'mortal', 'sudden', 'cardiac', 'autopsi', 'verifi', 'mortal', 'sudden', 'cardiac', 'mortal', 'gender', 'nonsudden', 'cardiac', 'mortal', 'nonsudden', 'cardiac', 'mortal', 'cerebrovascular', 'mortal']
221	22398	4.0	0.2838	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Observed  (O)  and expected  (E)  numbers of cancers, standardised incidence ratio  (SIR)  with 95% CI for colorectal cancer in first-degree relatives of patients with either ulcerative colitis or Crohn's disease in Sweden 195595	['observ', 'expect', 'number', 'cancer', 'standardis', 'incid', 'ratio', 'sir', 'ci', 'colorect', 'cancer', 'degre', 'relat', 'patient', 'ulcer', 'coliti', 'crohn', 'diseas', 'sweden']
222	6339	4.0	0.2836	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Global deaths, age-standardised death rates per 100000, YLL numbers, and age-standardised YLL rates per 100000, and percent change between 2006 and 2016 for both sexes combined for all GBD causes and levels 1 through 4 of the cause hierarchy	['global', 'death', 'age', 'standardis', 'death', 'rat', 'yll', 'number', 'age', 'standardis', 'yll', 'rat', 'percent', 'chang', 'sex', 'combin', 'gbd', 'caus', 'level', 'caus', 'hierarchi']
223	37566	4.0	0.2832	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Observed  (obs)  and expected  (exp)  numbers and standardised incidence ratios  (SIRs)  for all cancers in 42277 siblings of children with cancer, stratified by age at diagnosis	['observ', 'ob', 'expect', 'exp', 'number', 'standardis', 'incid', 'ratio', 'sir', 'cancer', 'sibl', 'children', 'cancer', 'stratifi', 'age', 'diagnosi']
224	39431	4.0	0.2829	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Female relative risk of death at ages 1574 years, by proxy-reported alcohol intake  (other drinkers vs reference drinkers, excluding never-drinkers)  and certified cause  (other causes vs control diseases)	['femal', 'relat', 'risk', 'death', 'age', 'year', 'proxi', 'report', 'alcohol', 'intak', 'drinker', 'vs', 'refer', 'drinker', 'exclud', 'drinker', 'certifi', 'caus', 'caus', 'vs', 'control', 'diseas']
225	37569	4.0	0.2829	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Observed  (obs)  number of sibling pairs with cancer and standardised incidence ratios  (SIR)  in siblings of children with cancer, followed-up in adulthood, stratified by type of cancer of index patient	['observ', 'ob', 'number', 'sibl', 'pair', 'cancer', 'standardis', 'incid', 'ratio', 'sir', 'sibl', 'children', 'cancer', 'follow', 'adulthood', 'stratifi', 'type', 'cancer', 'index', 'patient']
226	40495	4.0	0.2828	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Incidence rates  (per 100 person-years)  and HRs for all incident cancers, lung cancers, and non-lung cancers	['incid', 'rat', 'person', 'year', 'hrs', 'incid', 'cancer', 'lung', 'cancer', 'non', 'lung', 'cancer']
227	12119	4.0	0.2828	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Top ten causes of years lost due to disability  (YLDs)  in males, females, and both for ages 1014 years, 1519 years, and 2024 years, 1990, 2005, and 2013	['caus', 'year', 'lose', 'disabl', 'ylds', 'male', 'femal', 'age', 'year', 'year', 'year']
228	14286	4.0	0.2823	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Age-adjusted rates for all-cause, cardiovascular disease, and ischaemic heart disease mortality by sex-specific ascorbic acid quintile in men and women	['age', 'adjust', 'rat', 'caus', 'cardiovascular', 'diseas', 'ischaem', 'heart', 'diseas', 'mortal', 'sex', 'specif', 'ascorb', 'acid', 'quintil', 'men', 'women']
229	38572	4.0	0.2812	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Death rates  (per 1000 person years) , number of deaths, and mortality ratios for various causes of death among men aged 4455 years, according to diabetic  (NIDDM)  and non-diabetic  (non-DM)  status in the Whitehall, Paris Prospective, and Helsinki Policemen studies	['death', 'rat', 'person', 'year', 'number', 'death', 'mortal', 'ratio', 'caus', 'death', 'men', 'age', 'year', 'accord', 'diabet', 'niddm', 'non', 'diabet', 'non', 'dm', 'status', 'whitehal', 'pari', 'prospect', 'helsinki', 'policemen', 'studi']
230	10809	4.0	0.2811	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Decomposition analysis of the change of global years lived with disability  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific years lived with disability rates	['decomposit', 'analysi', 'chang', 'global', 'year', 'live', 'disabl', 'thousand', 'level', 'caus', 'total', 'popul', 'growth', 'popul', 'age', 'chang', 'age', 'specif', 'sex', 'specif', 'caus', 'specif', 'year', 'live', 'disabl', 'rat']
231	13353	4.0	0.2788	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Age-standardised 5-year net survival  (%)  with 95% CI: adults  (1599 years)  diagnosed with one of seven common malignancies  (breast, cervix, ovary, prostate, brain, myeloid, and lymphoid)  and children  (014 years)  diagnosed with one of three common malignancies  (brain, acute lymphoblastic leukaemia, and lymphoma)  by continent, country, and calendar period of diagnosis	['age', 'standardis', 'year', 'net', 'surviv', 'ci', 'adult', 'year', 'diagnos', 'seven', 'common', 'malign', 'breast', 'cervix', 'ovari', 'prostat', 'brain', 'myeloid', 'lymphoid', 'children', 'year', 'diagnos', 'common', 'malign', 'brain', 'acut', 'lymphoblast', 'leukaemia', 'lymphoma', 'contin', 'countri', 'calendar', 'period', 'diagnosi']
232	38122	4.0	0.2782	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Decomposition analysis of the change of DALY numbers  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific DALY rates for the Arab world	['decomposit', 'analysi', 'chang', 'dali', 'number', 'thousand', 'level', 'caus', 'total', 'popul', 'growth', 'popul', 'age', 'chang', 'age', 'specif', 'sex', 'specif', 'caus', 'specif', 'dali', 'rat', 'arab', 'world']
233	35707	4.0	0.2782	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Unadjusted breast-cancer incidence and mortality from incident tumours, with unadjusted and adjusted relative risks of breast-cancer death	['unadjust', 'breast', 'cancer', 'incid', 'mortal', 'incid', 'tumour', 'unadjust', 'adjust', 'relat', 'risk', 'breast', 'cancer', 'death']
234	11821	4.0	0.2758	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Relative risks  (95% CIs)  of death from all causes, cardiovascular disease  (CVD) , coronary heart disease  (CHD) , stroke, and external causes by typical dose per occasion in men who drink at least once a month	['relat', 'risk', 'cis', 'death', 'caus', 'cardiovascular', 'diseas', 'cvd', 'coronari', 'heart', 'diseas', 'chd', 'stroke', 'extern', 'caus', 'typic', 'dose', 'occas', 'men', 'drink', 'month']
235	45818	4.0	0.2756	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Substance use disorders as predictors of all-cause mortality, suicide, and deaths from accidents in people with schizophrenia, bipolar disorder, or depression	['substanc', 'use', 'disord', 'predictor', 'caus', 'mortal', 'suicid', 'death', 'accid', 'peopl', 'schizophrenia', 'bipolar', 'disord', 'depress']
236	25466	4.0	0.2748	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Observed and expected deaths from breast cancer  (diagnosed in all years)  in the initial cohort within 16 years, andrate ratios  (intervention centres vs combined comparison centres)	['observ', 'expect', 'death', 'breast', 'cancer', 'diagnos', 'year', 'initi', 'cohort', 'year', 'andrat', 'ratio', 'intervent', 'centr', 'vs', 'combin', 'comparison', 'centr']
237	10757	4.0	0.2738	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Age-standardised death rates, YLLs, and YLDs, and life expectancy at birth and HALE at birth for 1990 and 2010 for both sexes combined	['age', 'standardis', 'death', 'rat', 'ylls', 'ylds', 'life', 'expect', 'birth', 'hale', 'birth', 'sex', 'combin']
238	10744	4.0	0.2738	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Deaths  (in thousands)  and age-standardised death rates per 100000 for 231 causes in 1990 and 2010 for all ages, both sexes combined, and percentage change from 1990 to 2010 in China	['death', 'thousand', 'age', 'standardis', 'death', 'rat', 'caus', 'age', 'sex', 'combin', 'percentag', 'chang', 'china']
239	49469	4.0	0.272	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Cardiovascular disease mortality according to overweight at age 8 years  (childhood)  or at age 20 years  (young adult age) , or both	['cardiovascular', 'diseas', 'mortal', 'accord', 'overweight', 'age', 'year', 'childhood', 'age', 'year', 'young', 'adult', 'age']
240	37253	4.0	0.2715	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Crude and adjusted hazard ratios  (95% CI)  for death from any cause, death due to IHD, and admission for or death from IHD related to absolute values of birthweight	['crude', 'adjust', 'hazard', 'ratio', 'ci', 'death', 'caus', 'death', 'ihd', 'admiss', 'death', 'ihd', 'relat', 'absolut', 'valu', 'birthweight']
241	13366	4.0	0.2711	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Comparison of time trends in premature mortality before and during the 2008 economic crisis, by cause of death  (ICD-10)   *   and socioeconomic groups     and household car ownership, in the 2001 Spanish Census Cohort of people aged 1074 years	['comparison', 'time', 'trend', 'prematur', 'mortal', 'econom', 'crisi', 'caus', 'death', 'icd', 'socioeconom', 'group', 'household', 'car', 'ownership', 'spanish', 'census', 'cohort', 'peopl', 'age', 'year']
242	11823	4.0	0.27	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Relative risks  (95% Cis)  of death from all causes, cardiovascular diseases, and coronary heart disease, by frequency of drinking, stratified by typical dose per drinking occasion-drinkers only	['relat', 'risk', 'cis', 'death', 'caus', 'cardiovascular', 'diseas', 'coronari', 'heart', 'diseas', 'frequenc', 'drink', 'stratifi', 'typic', 'dose', 'drink', 'occas', 'drinker']
243	21935	4.0	0.2698	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Relative Rates  (95% CI)  of CVD Mortality, Incident CHD, and Total Mortality in Gender-Specific Quintiles of the Heart Rate-Adjusted QT	['relat', 'rat', 'ci', 'cvd', 'mortal', 'incid', 'chd', 'total', 'mortal', 'gender', 'specif', 'quintil', 'heart', 'rate', 'adjust', 'qt']
244	21066	4.0	0.2695	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Standardised incidence rates for endometrial and breast cancer per 1000 women over a 5-year period in current users and never users of HRT at recruitment	['standardis', 'incid', 'rat', 'endometri', 'breast', 'cancer', 'women', 'year', 'period', 'current', 'user', 'user', 'hrt', 'recruit']
245	12488	4.0	0.2695	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Exposure rates and odds ratios for wheeze and skin sensitivity to D pteronyssinus adjusted for age, sex, and urban or rural residence	['exposur', 'rat', 'odd', 'ratio', 'wheez', 'skin', 'sensit', 'pteronyssinus', 'adjust', 'age', 'sex', 'urban', 'rural', 'resid']
246	6386	4.0	0.2695	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Global deaths, disability-adjusted life-years, and age-standardised rates attributable to ambient particulate matter pollution in 2015	['global', 'death', 'disabl', 'adjust', 'life', 'year', 'age', 'standardis', 'rat', 'attribut', 'ambient', 'particul', 'matter', 'pollut']
247	10429	4.0	0.2671	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Global deaths for 235 causes in 1990 and 2013 for all ages and both sexes combined and age-standardised death rates	['global', 'death', 'caus', 'age', 'sex', 'combin', 'age', 'standardis', 'death', 'rat']
248	48121	4.0	0.2664	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Adjusted incidence rates, hazard ratios, and 95% CIs for cigarette smoking and lung cancer by sex	['adjust', 'incid', 'rat', 'hazard', 'ratio', 'cis', 'cigarett', 'smoke', 'lung', 'cancer', 'sex']
249	37252	4.0	0.2658	year, age, mortal, death, ratio, rat, relat, caus, incid, adjust	Crude and adjusted hazard ratios  (95% CI)  for death from any cause, death due to IHD, and admission for or death from IHD in relation to combinations of adverse obstetric outcomes	['crude', 'adjust', 'hazard', 'ratio', 'ci', 'death', 'caus', 'death', 'ihd', 'admiss', 'death', 'ihd', 'relat', 'combin', 'advers', 'obstetr', 'outcom']
250	50047	5.0	0.2782	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Diagnostic performance of Xpert MTB/RIF assay compared with smear microscopy, Lwenstein-Jensen medium, and Bactec MGIT960 system	['diagnost', 'perform', 'xpert', 'mtb', 'rif', 'assay', 'compar', 'smear', 'microscopi', 'lwenstein', 'jensen', 'medium', 'bactec', 'mgit']
251	31123	5.0	0.2713	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Subset Intravascular Ultrasound Analyses of Changes in the Cross-sectional Area of Lumen External Elastic Membrane and Plaque+Media  legend	['subset', 'intravascular', 'ultrasound', 'analys', 'chang', 'cross', 'section', 'area', 'lumen', 'extern', 'elast', 'membran', 'plaqu', 'media']
252	17003	5.0	0.2709	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Diagnostic accuracy of PECARN, CATCH, and CHALICE clinical decision rules when analysed using rule-specific inclusion criteria, exclusion criteria, predictor variables, and outcome measures	['diagnost', 'accuraci', 'pecarn', 'catch', 'chalic', 'clinic', 'decis', 'rule', 'analys', 'rule', 'specif', 'inclus', 'criteria', 'exclus', 'criteria', 'predictor', 'variabl', 'outcom', 'measur']
253	50046	5.0	0.2691	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Diagnostic performance of Xpert MTB/RIF assay compared with the combined reference standard  (smear microscopy, Lwenstein-Jensen medium, and Bactec MGIT960 system)	['diagnost', 'perform', 'xpert', 'mtb', 'rif', 'assay', 'compar', 'combin', 'refer', 'standard', 'smear', 'microscopi', 'lwenstein', 'jensen', 'medium', 'bactec', 'mgit']
254	14857	5.0	0.2624	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Per-protocol relative sensitivity and PPV of HPV versus Pap for a CIN2 or worse endpoint in different age groups with different cutoffs of HPV tests	['protocol', 'relat', 'sensit', 'ppv', 'hpv', 'versus', 'pap', 'cin', 'wors', 'endpoint', 'differ', 'age', 'group', 'differ', 'cutoff', 'hpv', 'test']
255	17660	5.0	0.2615	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	values on agreement of goitre diagnosis between examiners A, B, and C, between different classification systems in morning sessions, and between morning and afternoon sessions with the same classification system	['valu', 'agreement', 'goitr', 'diagnosi', 'examin', 'differ', 'classif', 'system', 'morn', 'session', 'morn', 'afternoon', 'session', 'classif']
256	31444	5.0	0.2603	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Axial Distribution of the Changes in Lumen, External Elastic Membrane and Plaque Plus Media Cross-Sectional Areas  (according to individual slices)	['axial', 'distribut', 'chang', 'lumen', 'extern', 'elast', 'membran', 'plaqu', 'plus', 'media', 'cross', 'section', 'area', 'accord', 'individu', 'slice']
257	7014	5.0	0.2591	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Proportion of participants reporting at least one severe rotavirus gastroenteritis  (RVGE)  episodes  (per protocol clinical definition)  and vaccine efficacy against severe RVGE during three efficacy periods  (according-to-protocol cohorts for the 2-years' efficacy subset)	['proport', 'particip', 'report', 'sever', 'rotavirus', 'gastroenter', 'rvge', 'episod', 'protocol', 'clinic', 'definit', 'vaccin', 'efficaci', 'sever', 'rvge', 'efficaci', 'period', 'accord', 'protocol', 'cohort', 'year', 'efficaci', 'subset']
258	14779	5.0	0.2581	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Performance of smear microscopy, clinic-based nurse-administered Xpert MTB/RIF, and laboratory-based technician-administered Xpert MTB/RIF, per treatment site and overall	['perform', 'smear', 'microscopi', 'clinic', 'base', 'nurs', 'administ', 'xpert', 'mtb', 'rif', 'laboratori', 'base', 'technician', 'administ', 'xpert', 'mtb', 'rif', 'treatment', 'site', 'overal']
259	17000	5.0	0.2544	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Inclusion and exclusion criteria, predictor variables, and outcome measures of PECARN, CATCH, and CHALICE clinical decision rules  8,9,12	['inclus', 'exclus', 'criteria', 'predictor', 'variabl', 'outcom', 'measur', 'pecarn', 'catch', 'chalic', 'clinic', 'decis', 'rule']
260	7015	5.0	0.2539	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Efficacy of RIX4414 against severe rotavirus gastroenteritis and severe gastroenteritis during the 2-years' efficacy period  (ATP cohort for the 2-years' efficacy subset)	['efficaci', 'rix', 'sever', 'rotavirus', 'gastroenter', 'sever', 'gastroenter', 'year', 'efficaci', 'period', 'atp', 'cohort', 'year', 'efficaci', 'subset']
261	32425	5.0	0.2508	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Epinephrine-Induced Changes in the max QTc-e, the min QTc-e, the QTc-eD, the max QTc-p, the min QTc-p, and the QTc-pD, Which Are Obtained From all 87-Leads, in the LQT1, LQT2, and Control Patients legend	['epinephrin', 'induc', 'chang', 'max', 'qtc', 'min', 'qtc', 'qtc', 'ed', 'max', 'qtc', 'min', 'qtc', 'qtc', 'pd', 'obtain', 'lead', 'lqt', 'lqt', 'control', 'patient']
262	8153	5.0	0.2439	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Effect of Using Different Cutoff Values for BNP on Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, and Accuracy in Predicting Death  (All-Cause Including the Cardiac Death)  in Referred and Not-Referred Groups	['effect', 'differ', 'cutoff', 'valu', 'bnp', 'sensit', 'specif', 'posit', 'predict', 'valu', 'negat', 'predict', 'valu', 'accuraci', 'predict', 'death', 'caus', 'includ', 'cardiac', 'death', 'refer', 'refer', 'group']
263	48083	5.0	0.2417	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Findings for all 441 women who were negative on initial colposcopy and were called back for a second colposcopy, including four-quadrant cervical biopsies and endocervical curettage, because of unsatisfactory or ASC-H+ cytology, positive careHPV  (RLU/cut-off ratio cut-point of 05) , or positive HC2 findings	['find', 'women', 'negat', 'initi', 'colposcopi', 'call', 'second', 'colposcopi', 'includ', 'quadrant', 'cervic', 'biopsi', 'endocerv', 'curettag', 'unsatisfactori', 'asc', 'cytolog', 'posit', 'carehpv', 'rlu', 'cut', 'ratio', 'cut', 'point', 'posit', 'hc', 'find']
264	35067	5.0	0.2412	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Determining Central SBP Cutoff Values Based on the Sensitivity and Specificity Associated With Cuff SBP Cutoff Values for Predicting Cardiovascular Mortality	['determin', 'central', 'sbp', 'cutoff', 'valu', 'base', 'sensit', 'specif', 'associ', 'cuff', 'sbp', 'cutoff', 'valu', 'predict', 'cardiovascular', 'mortal']
265	13462	5.0	0.2406	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Vaccine efficacy against any and severe rotavirus gastroenteritis according to detected rotavirus G types  (according-to-protocol cohort)	['vaccin', 'efficaci', 'sever', 'rotavirus', 'gastroenter', 'accord', 'detect', 'rotavirus', 'type', 'accord', 'protocol', 'cohort']
266	50189	5.0	0.2373	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	False-positive recall proportion shown according to double-reading protocols, and comparison of false-positive recall for screening integrating 3D mammography vs standard 2D mammography alone	['fals', 'posit', 'recal', 'proport', 'show', 'accord', 'doubl', 'read', 'protocol', 'comparison', 'fals', 'posit', 'recal', 'screen', 'integr', 'mammographi', 'vs', 'standard', 'mammographi']
267	22693	5.0	0.2373	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Comparisons of Area Under the ROC Curve Along With LR+ and LR for BNP or NT-proBNP Assays to Diagnose or Exclude Acute HF in Various Large Trials of Acute Dyspnea	['comparison', 'area', 'roc', 'curv', 'lr', 'lr', 'bnp', 'nt', 'probnp', 'assay', 'diagnos', 'exclud', 'acut', 'hf', 'larg', 'trial', 'acut', 'dyspnea']
268	41969	5.0	0.2368	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Sensitivity, Specificity, Positive Prognostic Value and Negative Prognostic Value of the Ability to Exercise to Bruce Stage 3 and a Duke Score 6	['sensit', 'specif', 'posit', 'prognost', 'valu', 'negat', 'prognost', 'valu', 'abil', 'exercis', 'bruce', 'stage', 'duke', 'score']
269	13461	5.0	0.2354	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Vaccine efficacy against any and severe rotavirus gastroenteritis, admission, and medical attention  (according-to-protocol cohort)	['vaccin', 'efficaci', 'sever', 'rotavirus', 'gastroenter', 'admiss', 'medic', 'attent', 'accord', 'protocol', 'cohort']
270	44016	5.0	0.2352	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	The Number of Patients With True-Positive, False-Negative, True-Negative, and False-Positive Test Results	['number', 'patient', 'true', 'posit', 'fals', 'negat', 'true', 'negat', 'fals', 'posit', 'test', 'result']
271	26404	5.0	0.2344	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Vaccine efficacy against cervical intraepithelial neoplasia grade 2 or more  (CIN2+) , or grade 3 or more  (CIN3+) , colposcopy referrals, and cervical excision procedures associated with human papillomavirus  (HPV) -16/18, five non-vaccine oncogenic types, and irrespective of HPV DNA in lesion	['vaccin', 'efficaci', 'cervic', 'intraepitheli', 'neoplasia', 'grade', 'cin', 'grade', 'cin', 'colposcopi', 'referr', 'cervic', 'excis', 'procedur', 'associ', 'human', 'papillomavirus', 'hpv', 'non', 'vaccin', 'oncogen', 'type', 'irrespect', 'hpv', 'dna', 'lesion']
272	47954	5.0	0.2341	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Relative sensitivity and specificity for CIN2+ and sensitivity for CIN3+ under different screening policies based on 220 CIN2 and 233 CIN3+ histologies detected in 18386 women in the revealed group in round 1	['relat', 'sensit', 'specif', 'cin', 'sensit', 'cin', 'differ', 'screen', 'polici', 'base', 'cin', 'cin', 'histolog', 'detect', 'women', 'reveal', 'group', 'round']
273	43289	5.0	0.2305	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Individual Components of Secondary Efficacy Endpoint of Persistent WRF	['individu', 'compon', 'secondari', 'efficaci', 'endpoint', 'persist', 'wrf']
274	25879	5.0	0.2301	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Sensitivities, specificities, positive and negative predictive values, and probabilities for comparison of differences in sensitivities	['sensit', 'specif', 'posit', 'negat', 'predict', 'valu', 'probabl', 'comparison', 'differ', 'sensit']
275	8078	5.0	0.23	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	One-Year Outcomes for the Lean, Overweight, and Obese Categories Stratified by Median BNP  (452 pg/ml)	['year', 'outcom', 'lean', 'overweight', 'obes', 'categori', 'stratifi', 'median', 'bnp', 'pg', 'ml']
276	49970	5.0	0.23	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Sensitivity, specificity, positive predictive values, and negative predictive values, by CSF -synuclein cutoff value	['sensit', 'specif', 'posit', 'predict', 'valu', 'negat', 'predict', 'valu', 'csf', 'synuclein', 'cutoff', 'valu']
277	38609	5.0	0.23	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Comparison of acid-fast-bacilli smear-positive, smear-negative, and smear-indeterminate patients	['comparison', 'acid', 'fast', 'bacilli', 'smear', 'posit', 'smear', 'negat', 'smear', 'indetermin', 'patient']
278	35490	5.0	0.2294	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Diagnostic sensitivities  (SE) , specificities  (SP) , false-negative  (FN)  and false-positive  (FP)  cases in each conventional BIT subtest and in combinations of two and three subtests  (n=52)	['diagnost', 'sensit', 'se', 'specif', 'sp', 'fals', 'negat', 'fn', 'fals', 'posit', 'fp', 'case', 'convent', 'bite', 'subtest', 'combin', 'subtest']
279	7016	5.0	0.22899999999999998	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Proportion of participants reporting severe rotavirus gastroenteritis  (RVGE)  episodes with a score of 11, 19 and 20 on the Vesikari scale and efficacy of vaccine during the 2-years' efficacy period  (according-to-protocol cohort for efficacy)	['proport', 'particip', 'report', 'sever', 'rotavirus', 'gastroenter', 'rvge', 'episod', 'score', 'vesikari', 'scale', 'efficaci', 'vaccin', 'year', 'efficaci', 'period', 'accord', 'protocol', 'cohort', 'efficaci']
280	47937	5.0	0.2288	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Pooled estimates of associations of TP53 codon 72 genotype and cervical histology of 33 studies; and invasive cervical cancer cases of 25 studies in subgroups of HPV status, ethnic group, and different quality criteria	['pool', 'estim', 'associ', 'tp', 'codon', 'genotyp', 'cervic', 'histolog', 'studi', 'invas', 'cervic', 'cancer', 'case', 'studi', 'subgroup', 'hpv', 'status', 'ethnic', 'group', 'differ', 'qualiti', 'criteria']
281	23583	5.0	0.2282	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Interim Operative Procedures Performed in 38 Stage I Operative Survivors Before Stage II Operation	['interim', 'oper', 'procedur', 'perform', 'stage', 'oper', 'survivor', 'stage', 'ii', 'oper']
282	22716	5.0	0.228	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Subgroup Analyses for Death, Major Amputation, Likelihood of Any Revascularization, and Likelihood of Endovascular Revascularization in the Study Cohort on the Basis of A PrioriDefined Subgroups	['subgroup', 'analys', 'death', 'major', 'amput', 'likelihood', 'likelihood', 'endovascular', 'studi', 'cohort', 'basi', 'prioridefin', 'subgroup']
283	20736	5.0	0.2279	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Summary of Studies That Used Measured EOAi to Assess VP-PM: Data of Moderate and Severe VP-PM Analyzed Separately	['summari', 'studi', 'measur', 'eoai', 'assess', 'vp', 'pm', 'data', 'moder', 'sever', 'vp', 'pm', 'analyz', 'separ']
284	32946	5.0	0.2279	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Ratio of Actual THV Stent Area Measured With CT to Nominal THV Area According to THV Size and Degree of Underfilling	['ratio', 'actual', 'thv', 'stent', 'area', 'measur', 'ct', 'nomin', 'thv', 'area', 'accord', 'thv', 'size', 'degre', 'underfil']
285	14781	5.0	0.2262	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Patients with a positive smear microscopy, Xpert MTB/RIF, or culture result, and days to result, per allocation group	['patient', 'posit', 'smear', 'microscopi', 'xpert', 'mtb', 'rif', 'cultur', 'result', 'day', 'result', 'alloc', 'group']
286	42792	5.0	0.2241	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Hazard Ratios for Different Endpoints per 1 SD Increase of ST2 Level or NT-proBNP Level  (on the Log2 Scale)  at Any Point in Time Using Repeated ST2 and Repeated NT-proBNP Measurements in a Joint Model	['hazard', 'ratio', 'differ', 'endpoint', 'sd', 'increas', 'st', 'level', 'nt', 'probnp', 'level', 'log', 'scale', 'point', 'time', 'repeat', 'st', 'repeat', 'nt', 'probnp', 'measur', 'joint', 'model']
287	39014	5.0	0.2227	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Stent thromboses according to ARC criteria for definite stent thrombosis and according to per-protocol definitions used in individual trials	['stent', 'thrombos', 'accord', 'arc', 'criteria', 'definit', 'stent', 'thrombosi', 'accord', 'protocol', 'definit', 'individu', 'trial']
288	7036	5.0	0.2227	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Sensitivity, specificity, and positive and negative predictive value for retinopathy at different fasting plasma glucose cutoffs	['sensit', 'specif', 'posit', 'negat', 'predict', 'valu', 'retinopathi', 'differ', 'fast', 'plasma', 'glucos', 'cutoff']
289	32514	5.0	0.2227	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Lumen Area, Vessel Area and Plaque Area of Cross Sections Arranged in the Six Sections  legend	['lumen', 'area', 'vessel', 'area', 'plaqu', 'area', 'cross', 'section', 'arrang', 'section']
290	28615	5.0	0.2227	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value of Various Cut-Off Values for the Indicated Parameters	['sensit', 'specif', 'posit', 'predict', 'valu', 'negat', 'predict', 'valu', 'cut', 'valu', 'indic', 'paramet']
291	26271	5.0	0.221	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Effect of the 9vHPV vaccine on the incidence of persistent infection, cervical disease, cervical cytological abnormalities, and cervical definitive therapy related to each HPV type in the per-protocol efficacy population	['effect', 'vhpv', 'vaccin', 'incid', 'persist', 'infect', 'cervic', 'diseas', 'cervic', 'cytolog', 'abnorm', 'cervic', 'definit', 'therapi', 'relat', 'hpv', 'type', 'protocol', 'efficaci', 'popul']
292	37368	5.0	0.2209	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	APOE genotypes of AD patients and aged non-AD patients positive or negative for HSV1 in brain  (frontal lobe and temporal lobe)	['apo', 'genotyp', 'ad', 'patient', 'age', 'non', 'ad', 'patient', 'posit', 'negat', 'hsv', 'brain', 'frontal', 'lobe', 'tempor', 'lobe']
293	26433	5.0	0.2208	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Efficacy against CIN2+ and CIN1+ associated with HPV16 or HPV18 in the total vaccinated cohort for efficacy	['efficaci', 'cin', 'cin', 'associ', 'hpv', 'hpv', 'total', 'vaccin', 'cohort', 'efficaci']
294	13463	5.0	0.21899999999999997	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Vaccine efficacy against all-cause severe gastroenteritis and admission  (according-to-protocol cohort for efficacy)	['vaccin', 'efficaci', 'caus', 'sever', 'gastroenter', 'admiss', 'accord', 'protocol', 'cohort', 'efficaci']
295	19980	5.0	0.2188	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Key Eligibility Criteria and Key Exclusion Criteria	['key', 'elig', 'criteria', 'key', 'exclus', 'criteria']
296	23451	5.0	0.2179	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Value of the Aortic Effective Regurgitant Orifice Area Calculated With the Proximal Isovelocity Surface Area Method and Quantitative Doppler and Two-Dimensional Echocardiographic Methods in the Overall Study Group and in Subgroups of Patients	['valu', 'aortic', 'effect', 'regurgit', 'orific', 'area', 'calcul', 'proxim', 'isoveloc', 'surfac', 'area', 'method', 'quantit', 'doppler', 'dimension', 'method', 'overal', 'studi', 'group', 'subgroup', 'patient']
297	35214	5.0	0.2179	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Percentage of Total Cross Section Represented by Plaque Area  (Difference Between Lumen Area and Area Delimited by Internal Elastic Lamina)  at Either 7 or 21 Days After Treatment with rhVEGF  (2 g/kg by a Single Intramuscular Injection)  or Albumin legend	['percentag', 'total', 'cross', 'section', 'repres', 'plaqu', 'area', 'differ', 'lumen', 'area', 'area', 'delimit', 'intern', 'elast', 'lamina', 'day', 'treatment', 'rhvegf', 'singl', 'intramuscular', 'inject', 'albumin']
298	20737	5.0	0.2174	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Summary of Studies That Use Measured EOAi to Assess VP-PM: Data of Moderate and Severe VP-PM Are Combined	['summari', 'studi', 'use', 'measur', 'eoai', 'assess', 'vp', 'pm', 'data', 'moder', 'sever', 'vp', 'pm', 'combin']
299	19612	5.0	0.2174	group, outcom, studi, accord, comparison, differ, primari, measur, valu, cohort	Comparison of ARIC JUPITER-Eligible Group, JUPITER Placebo Arm, and JUPITER Treated Arm: Event Rates	['comparison', 'aric', 'jupit', 'elig', 'group', 'jupit', 'placebo', 'arm', 'jupit', 'treat', 'arm', 'event', 'rat']
300	25085	6.0	0.3275	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Per Vessel Territory Diagnostic Accuracy of Coronary Computed Tomography Angiography, Transluminal Attenuation Gradient, Contrast Opacification Difference  (Maximum, Mean, and Minimum) , and Quantitative Coronary Angiography Compared With Fractional Flow Reserve  (N = 78)	['vessel', 'territori', 'diagnost', 'accuraci', 'coronari', 'comput', 'tomographi', 'angiographi', 'translumin', 'attenu', 'gradient', 'contrast', 'opacif', 'differ', 'maximum', 'mean', 'minimum', 'quantit', 'coronari', 'angiographi', 'compar', 'fraction', 'flow', 'reserv']
301	35304	6.0	0.3228	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Basal and  () Isoprenaline-Stimulated cAMP-levels of CHW-beta1 Cells in the Presence of Rabbit  (70 nmol/liter) , Mouse  (7 nmol/liter) , or Human Anti-beta1-ECII  (2 mol/liter)	['basal', 'isoprenalin', 'stimul', 'camp', 'level', 'chw', 'beta', 'cell', 'presenc', 'rabbit', 'nmol', 'liter', 'mous', 'nmol', 'liter', 'human', 'anti', 'beta', 'ecii', 'mol', 'liter']
302	30125	6.0	0.3212	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Basal and  () Isoprenaline-Stimulated cAMP-levels of CHW-beta1 Cells in the Presence of Rabbit  (70 nmol/liter) , Mouse  (7 nmol/liter) , or Human Anti-beta1-ECII  (2 mol/liter)	['basal', 'isoprenalin', 'stimul', 'camp', 'level', 'chw', 'beta', 'cell', 'presenc', 'rabbit', 'nmol', 'liter', 'mous', 'nmol', 'liter', 'human', 'anti', 'beta', 'ecii', 'mol', 'liter']
303	14352	6.0	0.3109	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Comparison of MR, Doppler Echocardiography and Catheterization-Derived Peak Pulmonary Vein Blood Flow Gradients  (mm Hg)  in Patients With Pulmonary Venous Pathway Obstruction	['comparison', 'mr', 'doppler', 'catheter', 'deriv', 'peak', 'pulmonari', 'vein', 'blood', 'flow', 'gradient', 'mm', 'hg', 'patient', 'pulmonari', 'venous', 'pathway', 'obstruct']
304	34684	6.0	0.309	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Individual Peak Myocardial Videointensity Data  (in gray scale units)  in Middle and Lateral Segments of Original Stenosis Zone and Adjacent Perfusion Bed in the Presence of One- and Two-Vessel Stenosis During Both Rest and Dobutamine Stress Echocardiography	['individu', 'peak', 'myocardi', 'videointens', 'data', 'gray', 'scale', 'unit', 'middl', 'later', 'segment', 'origin', 'stenosi', 'zone', 'adjac', 'perfus', 'bed', 'presenc', 'vessel', 'stenosi', 'rest', 'dobutamin', 'stress']
305	34429	6.0	0.3081	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Peak Tissue Doppler Velocity at Rest and During Dobutamine Stimulation Related to Results of 18F-Fluorodeoxyglucose Positron Emission Tomography for 192 Dyssynergic Segments at Rest	['peak', 'tissu', 'doppler', 'veloc', 'rest', 'dobutamin', 'stimul', 'relat', 'result', 'positron', 'emiss', 'tomographi', 'dyssynerg', 'segment', 'rest']
306	34651	6.0	0.308	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Comparison of Magnetic Resonance Imaging Findings Based on Dobutamine-Induced Systolic Wall Thickening and End-Diastolic Wall Thickness With Postrevascularization Recovery of Systolic Wall Thickening	['comparison', 'magnet', 'reson', 'imag', 'find', 'base', 'dobutamin', 'induc', 'systol', 'wall', 'thicken', 'end', 'diastol', 'wall', 'thick', 'recoveri', 'systol', 'wall', 'thicken']
307	31183	6.0	0.3076	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Coronary Flow Velocity Change in Coronary Aneurysms at Rest and Coronary Flow Reserve in 25 Patients With Kawasaki Disease and Aneurysmal Lesions in 29 Coronary Vessels  (group 2)	['coronari', 'flow', 'veloc', 'chang', 'coronari', 'aneurysm', 'rest', 'coronari', 'flow', 'reserv', 'patient', 'kawasaki', 'diseas', 'aneurysm', 'lesion', 'coronari', 'vessel', 'group']
308	34430	6.0	0.3047	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Peak Systolic SR Data at Rest and During Dobutamine Stimulation Related to Results of 18F-Fluorodeoxyglucose Positron Emission Tomography for 192 Dyssynergic Segments at Rest	['peak', 'systol', 'sr', 'data', 'rest', 'dobutamin', 'stimul', 'relat', 'result', 'positron', 'emiss', 'tomographi', 'dyssynerg', 'segment', 'rest']
309	31376	6.0	0.303	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Forearm Blood Flow During Brachial Artery Infusion of Saline, l-Arginine Alone, Nitroprusside, Acetylcholine and Acetylcholine Plus l-Arginine in Control Subjects and Hypertriglyceridemic Patients	['forearm', 'blood', 'flow', 'brachial', 'arteri', 'infus', 'salin', 'arginin', 'nitroprussid', 'acetylcholin', 'acetylcholin', 'plus', 'arginin', 'control', 'subject', 'patient']
310	31185	6.0	0.3022	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Coronary Flow Velocity Dynamics in Eight Patients With Kawasaki Disease and Ischemic Findings on Exercise Stress Testing and Normal Coronary Arteries on Angiography  (group 4)	['coronari', 'flow', 'veloc', 'dynam', 'patient', 'kawasaki', 'diseas', 'ischem', 'find', 'exercis', 'stress', 'test', 'normal', 'coronari', 'arteri', 'angiographi', 'group']
311	35297	6.0	0.2994	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Variable Inter-Compression Analysis Between the Repeated Measurements  (t1)  of 48 Coronary Obstructions in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series and the First Measurements  (t0)  in the Original Image Series legend	['variabl', 'inter', 'compress', 'analysi', 'repeat', 'measur', 'coronari', 'obstruct', 'origin', 'compress', 'decompress', 'cr', 'imag', 'seri', 'measur', 'origin', 'imag', 'seri']
312	35298	6.0	0.2994	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Variable Inter-Compression Analysis Between the Repeated Measurements  (t1)  of 48 Coronary Obstructions in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series and the First Measurements  (t0)  in the Original Image Series legend	['variabl', 'inter', 'compress', 'analysi', 'repeat', 'measur', 'coronari', 'obstruct', 'origin', 'compress', 'decompress', 'cr', 'imag', 'seri', 'measur', 'origin', 'imag', 'seri']
313	14351	6.0	0.2984	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Peak Pulmonary Vein Blood Flow Velocity  (cm/s)  of Patients With Pulmonary Venous Pathway Obstruction from MR Velocity Mapping and Doppler Echocardiography legend legend	['peak', 'pulmonari', 'vein', 'blood', 'flow', 'veloc', 'cm', 'patient', 'pulmonari', 'venous', 'pathway', 'obstruct', 'mr', 'veloc', 'map', 'doppler']
314	16381	6.0	0.2978	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Sensitivity of Dipyridamole, Dobutamine Stress Echo and Myocardial Perfusion Scintigraphy for the Detection of Isolated Left Anterior Descending Coronary Artery Disease With and Without Multivessel Disease legend	['sensit', 'dipyridamol', 'dobutamin', 'stress', 'echo', 'myocardi', 'perfus', 'scintigraphi', 'detect', 'isol', 'leav', 'anterior', 'descend', 'coronari', 'arteri', 'diseas', 'multivessel', 'diseas']
315	34056	6.0	0.2978	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Per-Vessel Territory Diagnostic Accuracy of QCA, Coronary CTA, Combined CTA+ CTP, Combined CTA+ TAG320, and MDCT-IP Assessments, Compared With FFR	['vessel', 'territori', 'diagnost', 'accuraci', 'qca', 'coronari', 'cta', 'combin', 'cta', 'ctp', 'combin', 'cta', 'tag', 'mdct', 'ip', 'assess', 'compar', 'ffr']
316	30890	6.0	0.2967	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Value of Response to Dobutamine at the First Week  (Wall Thickening With Dobutamine >2 mm)  for Predicting Normal Segmental Wall Motion at the Sixth Month  (Wall Thickening >2 mm)  Depending on the Transmural Extent of Necrosis	['valu', 'respons', 'dobutamin', 'week', 'wall', 'thicken', 'dobutamin', 'mm', 'predict', 'normal', 'segment', 'wall', 'motion', 'sixth', 'month', 'wall', 'thicken', 'mm', 'depend', 'transmur', 'extent', 'necrosi']
317	31662	6.0	0.2944	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Diagnostic Performance of Multislice Spiral Computed Tomography Coronary Angiography for the Detection of Significant Obstructive Lesions	['diagnost', 'perform', 'multislic', 'spiral', 'comput', 'tomographi', 'coronari', 'angiographi', 'detect', 'signific', 'obstruct', 'lesion']
318	30373	6.0	0.2938	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Contractile Responses to Potassium  (K+125 mmol/liter)  Phenylephrine  (PE, 1 mol/liter)  and Angiotensin II  (1 and 100 nmol/liter) , and Dilator Responses to Acetylcholine  (10 mol/liter)  in Human Internal Mammary Artery Segments From Patients With the DD or the II/ID Genotype legend	['contractil', 'respons', 'potassium', 'mmol', 'liter', 'phenylephrin', 'pe', 'mol', 'liter', 'angiotensin', 'ii', 'nmol', 'liter', 'dilat', 'respons', 'acetylcholin', 'mol', 'liter', 'human', 'intern', 'mammari', 'arteri', 'segment', 'patient', 'dd', 'ii', 'id', 'genotyp']
319	31207	6.0	0.2921	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Comparison of Thallium-201 and Technetium-99m Tetrofosmin Single-Photon Emission Computed Tomographic Dipyridamole Imaging Data in 364 Scan Segments	['comparison', 'thallium', 'technetium', 'tetrofosmin', 'singl', 'photon', 'emiss', 'comput', 'tomograph', 'dipyridamol', 'imag', 'data', 'scan', 'segment']
320	34431	6.0	0.2897	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Diagnostic Accuracy of Two-Dimensional Dobutamine Stress Echocardiography, TDI and SRI for Detection of Viability Determined by 18F-Flurodeoxyglucose Positron Emission Tomography	['diagnost', 'accuraci', 'dimension', 'dobutamin', 'stress', 'tdi', 'sri', 'detect', 'viabil', 'determin', 'positron', 'emiss', 'tomographi']
321	35296	6.0	0.2873	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Variable Inter-Compression Analysis Between the Repeated Calibrations  (t1)  of 48 Catheters in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series and the First Calibrations  (t0)  in the Original Image Series legend	['variabl', 'inter', 'compress', 'analysi', 'repeat', 'calibr', 'cathet', 'origin', 'compress', 'decompress', 'cr', 'imag', 'seri', 'calibr', 'origin', 'imag', 'seri']
322	42205	6.0	0.2868	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Pulse, Systolic Blood Pressure, End-Tidal Carbon Dioxide Concentration and Arterial Oxygen Saturation at Rest, at 3 Minutes of Exercise, at 6 Minutes of Exercise and at Peak Exercise With Placebo and Dihydrocodeine	['puls', 'systol', 'blood', 'pressur', 'end', 'tidal', 'carbon', 'dioxid', 'concentr', 'arteri', 'oxygen', 'satur', 'rest', 'minut', 'exercis', 'minut', 'exercis', 'peak', 'exercis', 'placebo', 'dihydrocodein']
323	35100	6.0	0.2866	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Diagnostic Accuracy of Whole-Heart Coronary Magnetic Resonance Angiography to Detect Stenoses of 50% in 113 Patients Who Completed Acquisition of Coronary Magnetic Resonance Data	['diagnost', 'accuraci', 'heart', 'coronari', 'magnet', 'reson', 'angiographi', 'detect', 'stenos', 'patient', 'complet', 'acquisit', 'coronari', 'magnet', 'reson', 'data']
324	7303	6.0	0.2849	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Analysis of Significance and Prognostic Value of Systolic Blood Pressure, Diastolic Blood Pressure and Mean Arterial Blood Pressure Obtained During Dobutamine Infusion  a	['analysi', 'signific', 'prognost', 'valu', 'systol', 'blood', 'pressur', 'diastol', 'blood', 'pressur', 'mean', 'arteri', 'blood', 'pressur', 'obtain', 'dobutamin', 'infus']
325	23712	6.0	0.2815	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Analysis of the Influence of Coronary Diameter, Image Quality, and Coronary Calcium of the Diagnostic Performance of 64-Slice CTCA for the Detection of 50% Stenosis on QCA in the Per-Segment Analysis  (95% CI)	['analysi', 'influenc', 'coronari', 'diamet', 'imag', 'qualiti', 'coronari', 'calcium', 'diagnost', 'perform', 'slice', 'ctca', 'detect', 'stenosi', 'qca', 'segment', 'analysi', 'ci']
326	35026	6.0	0.2802	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Cutpoints for Electron Beam Computed Tomographic Coronary Calcium Scores for Sensitivity of 90% and Associated Specificity and for Electron Beam Computed Tomographic Quantified Coronary Calcium Scores for Specificity of 90% and Associated Sensitivity as a Function of Decade of Associated Maximal Angiographic Lumen Stenoses	['cutpoint', 'electron', 'beam', 'comput', 'tomograph', 'coronari', 'calcium', 'score', 'sensit', 'associ', 'specif', 'electron', 'beam', 'comput', 'tomograph', 'quantifi', 'coronari', 'calcium', 'score', 'specif', 'associ', 'sensit', 'function', 'decad', 'associ', 'maxim', 'angiograph', 'lumen', 'stenos']
327	31327	6.0	0.2799	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Relative Coronary Flow Reserves for Adenosine and Papaverine and Volumetric Coronary Flow Reserve for Acetylcholine in Five Patients with the Adenosine Defect and Twenty-Four Control Subjects	['relat', 'coronari', 'flow', 'reserv', 'adenosin', 'papaverin', 'volumetr', 'coronari', 'flow', 'reserv', 'acetylcholin', 'patient', 'adenosin', 'defect', 'control', 'subject']
328	19268	6.0	0.2791	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	PET Flow and Glucose Uptake, Percent MIBI Uptake, Ventricular Function and Percent Fibrosis in Anterior Wall Biopsy Specimen	['pet', 'flow', 'glucos', 'uptak', 'percent', 'mibi', 'uptak', 'ventricular', 'function', 'percent', 'fibrosi', 'anterior', 'wall', 'biopsi', 'specimen']
329	12358	6.0	0.2782	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Relationship Between Coronary Artery Lesions and Perfusion Defects on Thallium-201 Single Photon Emission Computed Tomography	['relationship', 'coronari', 'arteri', 'lesion', 'perfus', 'defect', 'thallium', 'singl', 'photon', 'emiss', 'comput', 'tomographi']
330	33824	6.0	0.2774	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Intensity of Single-Photon Emission Computed Tomographic Perfusion Defects, Wall Motion Abnormalities and Contrast Effects on Patients in Each Randomized Dosage Group legend	['intens', 'singl', 'photon', 'emiss', 'comput', 'tomograph', 'perfus', 'defect', 'wall', 'motion', 'abnorm', 'contrast', 'effect', 'patient', 'random', 'dosag', 'group']
331	23478	6.0	0.2774	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Comparison Between Intravenous Electron-Beam Coronary Angiography and Selective Coronary Angiography in 221 Segments Comprising the Proximal and Mid Major Coronary Arteries  (eight-segment model)  in 28 Patients  legend	['comparison', 'intraven', 'electron', 'beam', 'coronari', 'angiographi', 'select', 'coronari', 'angiographi', 'segment', 'compris', 'proxim', 'mid', 'major', 'coronari', 'arteri', 'segment', 'model', 'patient']
332	19562	6.0	0.2764	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Diagnostic Performance of SPECT, CMR, and PET Perfusion Imaging on Patient and Coronary Artery Territory Basis	['diagnost', 'perform', 'spect', 'cmr', 'pet', 'perfus', 'imag', 'patient', 'coronari', 'arteri', 'territori', 'basi']
333	31661	6.0	0.2755	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Results: Detection of Significant  (50%)  Stenoses With 16-Row Multislice Spiral Computed Tomography Coronary Angiography	['result', 'detect', 'signific', 'stenos', 'row', 'multislic', 'spiral', 'comput', 'tomographi', 'coronari', 'angiographi']
334	19154	6.0	0.273	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Quantitative Measurements of Wall Thickness, Simulated Wall Motion and Simulated Wall Thickening Using the Variable Thickness Heart Phantom	['quantit', 'measur', 'wall', 'thick', 'simul', 'wall', 'motion', 'simul', 'wall', 'thicken', 'variabl', 'thick', 'heart', 'phantom']
335	35019	6.0	0.272	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Detection of Significant Coronary Stenoses by Electron Beam Computed Tomography Versus Coronary Angiography for 267 Analyzed Segments	['detect', 'signific', 'coronari', 'stenos', 'electron', 'beam', 'comput', 'tomographi', 'versus', 'coronari', 'angiographi', 'analyz', 'segment']
336	31017	6.0	0.2711	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Results of Quantitative Computerized Digital Analysis of Micro-CT Images by Normal and the Balloon-injured Coronary Arteries	['result', 'quantit', 'computer', 'digit', 'analysi', 'micro', 'ct', 'imag', 'normal', 'balloon', 'injur', 'coronari', 'arteri']
337	33827	6.0	0.2711	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Correlation of Single-Photon Emission Computed Tomography  (SPECT)  With Harmonic Myocardial Contrast Echocardiography in the Triggered Mode, According to the Correlation of SPECT with Wall Motion Analysis  (After Exclusion of Nondiagnostic Studies)  legend	['correl', 'singl', 'photon', 'emiss', 'comput', 'tomographi', 'spect', 'harmon', 'myocardi', 'contrast', 'trigger', 'mode', 'accord', 'correl', 'spect', 'wall', 'motion', 'analysi', 'exclus', 'nondiagnost', 'studi']
338	16844	6.0	0.2711	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Performance Indexes of CTCA and SPECT/CTCA for Detection of Hemodynamically Significant Coronary Lesions in 170 Segments in 44 Patients	['perform', 'index', 'ctca', 'spect', 'ctca', 'detect', 'hemodynam', 'signific', 'coronari', 'lesion', 'segment', 'patient']
339	12072	6.0	0.2711	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Results of Magnetic Resonance Imaging Parameters and uptake by Positron Emission Tomography, According to Wall Motion	['result', 'magnet', 'reson', 'imag', 'paramet', 'uptak', 'positron', 'emiss', 'tomographi', 'accord', 'wall', 'motion']
340	31302	6.0	0.2708	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Mitral Inflow, Pulmonary Venous Flow and Mitral Annulus Velocity in 59 Normal Volunteers	['mitral', 'inflow', 'pulmonari', 'venous', 'flow', 'mitral', 'annulus', 'veloc', 'normal', 'volunt']
341	11410	6.0	0.2703	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Diagnostic Performance of RT-MCE and SPECT to Detect Significant Coronary Artery Disease in Individual Vascular Territories	['diagnost', 'perform', 'rt', 'mce', 'spect', 'detect', 'signific', 'coronari', 'arteri', 'diseas', 'individu', 'vascular', 'territori']
342	9891	6.0	0.2694	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Diagnostic Accuracy of Coronary CTA for the Detection of Acute Coronary Syndrome and Myocardial Infarction During Index Hospitalization Among Patients With Acute Chest Pain Based on the Presence of Any Coronary Plaque or the Presence of Coronary Artery Stenosis  (>50% Luminal Narrowing)	['diagnost', 'accuraci', 'coronari', 'cta', 'detect', 'acut', 'coronari', 'syndrom', 'myocardi', 'infarct', 'index', 'hospit', 'patient', 'acut', 'chest', 'pain', 'base', 'presenc', 'coronari', 'plaqu', 'presenc', 'coronari', 'arteri', 'stenosi', 'lumin', 'narrow']
343	22436	6.0	0.2691	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Results of Coronary Artery Segment Classification and Stenosis Assessment by Contrast-enhanced Magnetic Resonance Coronary Angiography Compared With Conventional Invasive Angiography  (n = 350)  legend	['result', 'coronari', 'arteri', 'segment', 'classif', 'stenosi', 'assess', 'contrast', 'enhanc', 'magnet', 'reson', 'coronari', 'angiographi', 'compar', 'convent', 'invas', 'angiographi']
344	11242	6.0	0.26899999999999996	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Diagnostic Performance of Multi-Slice Computed Tomography Coronary Angiography to Detect 50% Stenoses	['diagnost', 'perform', 'multi', 'slice', 'comput', 'tomographi', 'coronari', 'angiographi', 'detect', 'stenos']
345	34493	6.0	0.2678	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Comparison of MCE, SPECT, Wall Motion and the Combination of MCE and Wall Motion With Results of Coronary Angiography: Analysis by Patients  (n = 44)  legend	['comparison', 'mce', 'spect', 'wall', 'motion', 'combin', 'mce', 'wall', 'motion', 'result', 'coronari', 'angiographi', 'analysi', 'patient']
346	34057	6.0	0.2664	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Per-Vessel Diagnostic Accuracy of CTA+ TAG320, CTA+ CTP, and MDCT-IP Methods in 97 Vessels	['vessel', 'diagnost', 'accuraci', 'cta', 'tag', 'cta', 'ctp', 'mdct', 'ip', 'method', 'vessel']
347	29720	6.0	0.2658	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Mean Myocardial Perfusion Measures Across Number of Coronary Arteries Containing Calcium  (Coronary Artery Calcium Score >0 in the Respective Artery)  in Subjects With No Clinical Coronary Heart Disease From The Multi-Ethnic Study of Atherosclerosis	['mean', 'myocardi', 'perfus', 'measur', 'number', 'coronari', 'arteri', 'contain', 'calcium', 'coronari', 'arteri', 'calcium', 'score', 'respect', 'arteri', 'subject', 'clinic', 'coronari', 'heart', 'diseas', 'multi', 'ethnic', 'studi', 'atherosclerosi']
348	42118	6.0	0.2654	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Comparison of Superior Vena Cava Peak Forward and Reverse Flow Velocity in Chronic Obstructive Pulmonary Disease and Constrictive Pericarditis  legend	['comparison', 'superior', 'vena', 'cava', 'peak', 'forward', 'revers', 'flow', 'veloc', 'chronic', 'obstruct', 'pulmonari', 'diseas', 'constrict', 'pericard']
349	17967	6.0	0.265	data, coronari, patient, paramet, test, result, angiograph, arteri, hemodynam, blood	Accuracy of Multislice Computed Tomography for the Detection of Significant Coronary Plaque    : Comparison With IVUS for the Entire Region of Interest and for its 5-mm Subsegments	['accuraci', 'multislic', 'comput', 'tomographi', 'detect', 'signific', 'coronari', 'plaqu', 'comparison', 'ivus', 'entir', 'region', 'mm', 'subseg']
350	7411	7.0	0.2897	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Overview of Used Risk Scores: Risk Factors Used in CHA2DS2-VASc Risk Score and CHADS2 Risk Score	['overview', 'risk', 'score', 'risk', 'factor', 'cha', 'ds', 'vasc', 'risk', 'score', 'chad', 'risk', 'score']
351	20571	7.0	0.2854	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Comparison of CHA2DS2-VASc and CHA2DS2-VASc-R Scores in Predicting Stroke: Relative Hazard Associated With 1-Point Increase in Stroke Risk Score, and C-Statistic	['comparison', 'cha', 'ds', 'vasc', 'cha', 'ds', 'vasc', 'score', 'predict', 'stroke', 'relat', 'hazard', 'associ', 'point', 'increas', 'stroke', 'risk', 'score', 'statist']
352	35369	7.0	0.2838	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Comparison of CHA2DS2-VASc and CHA2DS2-VASc-R Scores in Predicting Stroke: Relative Hazard Associated With 1-Point Increase in Stroke Risk Score, and C-Statistic	['comparison', 'cha', 'ds', 'vasc', 'cha', 'ds', 'vasc', 'score', 'predict', 'stroke', 'relat', 'hazard', 'associ', 'point', 'increas', 'stroke', 'risk', 'score', 'statist']
353	20570	7.0	0.2822	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Hazard of Stroke by Race/Ethnicity, Relative to White Patients, After Controlling for CHA2DS2-VASc Score  (Model 1)  and CHA2DS2-VASc Score Plus Anticoagulant Use  (Model 2)	['hazard', 'stroke', 'race', 'ethnic', 'relat', 'white', 'patient', 'control', 'cha', 'ds', 'vasc', 'score', 'model', 'cha', 'ds', 'vasc', 'score', 'plus', 'anticoagul', 'use', 'model']
354	35368	7.0	0.2822	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Hazard of Stroke by Race/Ethnicity, Relative to White Patients, After Controlling for CHA2DS2-VASc Score  (Model 1)  and CHA2DS2-VASc Score Plus Anticoagulant Use  (Model 2)	['hazard', 'stroke', 'race', 'ethnic', 'relat', 'white', 'patient', 'control', 'cha', 'ds', 'vasc', 'score', 'model', 'cha', 'ds', 'vasc', 'score', 'plus', 'anticoagul', 'use', 'model']
355	12302	7.0	0.2782	risk, associ, factor, control, score, trial, status, accord, distribut, assess	ORunadjusted and ORadj-2 of morbidity at 30 days for patients with anaemia or risk factors and anaemia and risk factors, compared with reference populations of patients with neither anaemia nor risk factors	['orunadjust', 'oradj', 'morbid', 'day', 'patient', 'anaemia', 'risk', 'factor', 'anaemia', 'risk', 'factor', 'compar', 'refer', 'popul', 'patient', 'anaemia', 'risk', 'factor']
356	15492	7.0	0.2664	risk, associ, factor, control, score, trial, status, accord, distribut, assess	7-day risk of stroke stratified according to ABCD score at first assessment in all referrals with suspected TIA to OXVASC and risk of stroke before scheduled clinic appointment in all referrals with suspected TIA to the non-OXVASC hospital-referred weekly TIA clinic	['day', 'risk', 'stroke', 'stratifi', 'accord', 'abcd', 'score', 'assess', 'referr', 'suspect', 'tia', 'oxvasc', 'risk', 'stroke', 'schedul', 'clinic', 'appoint', 'referr', 'suspect', 'tia', 'non', 'oxvasc', 'hospit', 'refer', 'week', 'tia', 'clinic']
357	12301	7.0	0.2651	risk, associ, factor, control, score, trial, status, accord, distribut, assess	ORunadjusted and ORadj-2 of mortality at 30 days for patients with anaemia or risk factors and anaemia and risk factors, compared with reference populations of patients with neither anaemia nor risk factors	['orunadjust', 'oradj', 'mortal', 'day', 'patient', 'anaemia', 'risk', 'factor', 'anaemia', 'risk', 'factor', 'compar', 'refer', 'popul', 'patient', 'anaemia', 'risk', 'factor']
358	5609	7.0	0.2641	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Association of Age, Sex, and Race/Ethnicity With ABI Category, and Age-, Sex-, and Race/Ethnicity-Adjusted Distributions of Risk Factors by ABI Category	['associ', 'age', 'sex', 'race', 'ethnic', 'abi', 'categori', 'age', 'sex', 'race', 'ethnic', 'adjust', 'distribut', 'risk', 'factor', 'abi', 'categori']
359	31531	7.0	0.2585	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Association of TG or TG Genetic Risk Score With CAC 75th Percentile in the FHS	['associ', 'tg', 'tg', 'genet', 'risk', 'score', 'cac', 'th', 'percentil', 'fhs']
360	23698	7.0	0.256	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Relative Risk of Incident CAC and Mean Change in CAC Score With Varying FRS and RRS Groups According to Low- and High-Risk Groups Classified by FRS and RRS, Respectively	['relat', 'risk', 'incid', 'cac', 'mean', 'chang', 'cac', 'score', 'vari', 'frs', 'rrs', 'group', 'accord', 'low', 'high', 'risk', 'group', 'classifi', 'frs', 'rrs', 'respect']
361	38427	7.0	0.2535	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Pooled analysis of the early risk of recurrent vascular events, given per time period after randomisation, in trials of aspirin versus control in secondary prevention after transient ischaemic attack and ischaemic stroke	['pool', 'analysi', 'earli', 'risk', 'recurr', 'vascular', 'event', 'give', 'time', 'period', 'randomis', 'trial', 'aspirin', 'versus', 'control', 'secondari', 'prevent', 'transient', 'ischaem', 'attack', 'ischaem', 'stroke']
362	19874	7.0	0.2531	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Risk of Ischemic Stroke in Patients with an ATRIA Score of 0 to 5, Stratified on the Basis of Their CHA2DS2-VASc Scores	['risk', 'ischem', 'stroke', 'patient', 'atria', 'score', 'stratifi', 'basi', 'cha', 'ds', 'vasc', 'score']
363	39492	7.0	0.2517	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Western Aphasia Battery  (WAB)  subtest scores before and after resection for patients with dominant hemispheric tumour who were dysphasic  (aphasia quotient <937)  before resection	['western', 'aphasia', 'batteri', 'wab', 'subtest', 'score', 'resect', 'patient', 'domin', 'hemispher', 'tumour', 'dysphas', 'aphasia', 'quotient', 'resect']
364	42947	7.0	0.25	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Risk of Ischemic Stroke in AF Female Patients  (CHA2DS2-VASc Score of 2: Female Plus 1 Additional Stroke Risk Factor)	['risk', 'ischem', 'stroke', 'af', 'femal', 'patient', 'cha', 'ds', 'vasc', 'score', 'femal', 'plus', 'addit', 'stroke', 'risk', 'factor']
365	39491	7.0	0.2483	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Western Aphasia Battery  (WAB)  summary scores before and after resection for patients with dominant hemispheric tumour who were dysphasic  (aphasia quotient <937)  before resection	['western', 'aphasia', 'batteri', 'wab', 'summari', 'score', 'resect', 'patient', 'domin', 'hemispher', 'tumour', 'dysphas', 'aphasia', 'quotient', 'resect']
366	39335	7.0	0.24600000000000002	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Severity and duration of upper-respiratory-tract  (URT)  and lower-respiratory-tract  (LRT)  symptoms associated with rhinovirus infection	['sever', 'durat', 'upper', 'respiratori', 'tract', 'urt', 'lower', 'respiratori', 'tract', 'lrt', 'symptom', 'associ', 'rhinovirus', 'infect']
367	35577	7.0	0.2428	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Statistical associations  (p<10107)  between Illumina SNPs and circulating concentrations of LDL cholesterol in a genome-wide meta-analysis of three UK study populations consisting of up to 4337 participants	['statist', 'associ', 'illumina', 'snps', 'circul', 'concentr', 'ldl', 'cholesterol', 'genom', 'wide', 'meta', 'analysi', 'uk', 'studi', 'popul', 'consist', 'particip']
368	45319	7.0	0.2421	risk, associ, factor, control, score, trial, status, accord, distribut, assess	c statistics  (with 95% CI)  for early stroke discrimination with ABCD2, ABCD2-I, and ABCD3-I scores at each timepoint after transient ischaemic attack	['statist', 'ci', 'earli', 'stroke', 'discrimin', 'abcd', 'abcd', 'abcd', 'score', 'timepoint', 'transient', 'ischaem', 'attack']
369	31528	7.0	0.2421	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Association of Lipid Measures or Genetic Risk Scores With CAC 75th Percentile in the Pooled FHS Offspring and Third-Generation Cohorts  (n = 3,110)	['associ', 'lipid', 'measur', 'genet', 'risk', 'score', 'cac', 'th', 'percentil', 'pool', 'fhs', 'offspr', 'generat', 'cohort']
370	7414	7.0	0.2418	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Ischemic Stroke Event Rates Stratified by the Sum of Points for ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores	['ischem', 'stroke', 'event', 'rat', 'stratifi', 'sum', 'point', 'atria', 'chad', 'cha', 'ds', 'vasc', 'risk', 'score']
371	39804	7.0	0.2415	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Randomised controlled trials included in the systematic review and network meta-analysis	['randomis', 'control', 'trial', 'includ', 'systemat', 'review', 'network', 'meta', 'analysi']
372	35576	7.0	0.2412	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Statistical associations  (p<10107)  between Affymetrix SNPs and circulating concentrations of LDL cholesterol in a genome-wide meta-analysis of five study populations consisting of up to 11685 participants	['statist', 'associ', 'affymetrix', 'snps', 'circul', 'concentr', 'ldl', 'cholesterol', 'genom', 'wide', 'meta', 'analysi', 'studi', 'popul', 'consist', 'particip']
373	38428	7.0	0.2408	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Pooled analysis of the effect of any aspirin versus control in secondary prevention after TIA and ischaemic stroke on the early risk of any recurrent ischaemic stroke and on disabling or fatal ischaemic stroke stratified by the nature of the presenting event  (TIA and minor stroke vs major stroke)  and by time from presenting event to randomisation  (14 days vs >14 days)	['pool', 'analysi', 'effect', 'aspirin', 'versus', 'control', 'secondari', 'prevent', 'tia', 'ischaem', 'stroke', 'earli', 'risk', 'recurr', 'ischaem', 'stroke', 'disabl', 'fatal', 'ischaem', 'stroke', 'stratifi', 'natur', 'present', 'event', 'tia', 'minor', 'stroke', 'vs', 'major', 'stroke', 'time', 'present', 'event', 'randomis', 'day', 'vs', 'day']
374	25142	7.0	0.2406	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Prevalence of Solo and Combination Antiplatelet Prescription in AF Patients at Intermediate to High Risk of Stroke, Stratified by Prescription of Aspirin Versus OAC in the Overall CHADS2 Score2 and CHA2DS2-VASc Score2 Cohorts and Subcohorts of Patients With and Without Any Coronary Heart Disease Risk Equivalent	['preval', 'solo', 'combin', 'antiplatelet', 'prescript', 'af', 'patient', 'intermedi', 'high', 'risk', 'stroke', 'stratifi', 'prescript', 'aspirin', 'versus', 'oac', 'overal', 'chad', 'score', 'cha', 'ds', 'vasc', 'score', 'cohort', 'subcohort', 'patient', 'coronari', 'heart', 'diseas', 'risk', 'equival']
375	35390	7.0	0.2396	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Adjuvant radiotherapy received  (within 3 months after surgery) , nodes removed, nodal status, and external-beam radiotherapy  (EBRT)  received in node-positive patients by risk group defined according to ASTEC radiotherapy eligibility	['adjuv', 'radiotherapi', 'receiv', 'month', 'surgeri', 'nod', 'remov', 'nodal', 'status', 'extern', 'beam', 'radiotherapi', 'ebrt', 'receiv', 'node', 'posit', 'patient', 'risk', 'group', 'defin', 'accord', 'astec', 'radiotherapi', 'elig']
376	35929	7.0	0.239	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Distribution of WHODAS disability scores by dementia status and site, and the effects of dementia  (main effect of 10/66 dementia, modified by DSM-IV dementia)  on WHODAS score	['distribut', 'whoda', 'disabl', 'score', 'dementia', 'status', 'site', 'effect', 'dementia', 'main', 'effect', 'dementia', 'modifi', 'dsm', 'iv', 'dementia', 'whoda', 'score']
377	41407	7.0	0.2385	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Drug Prescription Distribution Among Responders by Haplotype Arg389Arg-Ser49Ser  (n = 85)  and Arg389Gly-Ser49Ser  (n = 97)	['drug', 'prescript', 'distribut', 'respond', 'haplotyp', 'arg', 'arg', 'ser', 'ser', 'arg', 'gli', 'ser', 'ser']
378	47947	7.0	0.2375	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Vascular risk factors and retinal vascular signs in patients with lacunar and other ischaemic stroke	['vascular', 'risk', 'factor', 'retin', 'vascular', 'sign', 'patient', 'lacunar', 'ischaem', 'stroke']
379	36176	7.0	0.2375	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Availability of data from randomised trials that began before 1990 of adjuvant tamoxifen versus no adjuvant tamoxifen	['avail', 'data', 'randomis', 'trial', 'begin', 'adjuv', 'tamoxifen', 'versus', 'adjuv', 'tamoxifen']
380	39490	7.0	0.2365	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Western Aphasia Battery  (WAB)  summary scores before and after resection for patients whose language was classified as normal  (aphasia quotient 938)  before resection	['western', 'aphasia', 'batteri', 'wab', 'summari', 'score', 'resect', 'patient', 'languag', 'classifi', 'normal', 'aphasia', 'quotient', 'resect']
381	35578	7.0	0.2359	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Imputed SNPs showing genome-wide statistical association  (p<10107)  with circulating concentrations of LDL cholesterol; meta-analysis of four study populations consisting of up to 9988 participants	['imput', 'snps', 'show', 'genom', 'wide', 'statist', 'associ', 'circul', 'concentr', 'ldl', 'cholesterol', 'meta', 'analysi', 'studi', 'popul', 'consist', 'particip']
382	38606	7.0	0.2352	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Risk of transient ischaemic attack according to use of HRT and identified risk factors in women aged 4564 years	['risk', 'transient', 'ischaem', 'attack', 'accord', 'use', 'hrt', 'identifi', 'risk', 'factor', 'women', 'age', 'year']
383	18492	7.0	0.2334	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Prevalence Rates of Major Cardiovascular Risk Factors in Patients With Familial P-CAD and Their Respective Age- and Gender-Matched Control Subjects, According to Parental History of CAD in Patients with Familial P-CAD *	['preval', 'rat', 'major', 'cardiovascular', 'risk', 'factor', 'patient', 'famili', 'cad', 'respect', 'age', 'gender', 'match', 'control', 'subject', 'accord', 'parent', 'histori', 'cad', 'patient', 'famili', 'cad']
384	27220	7.0	0.2334	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Independent contributions to the risk of a second ischaemic stroke for prothrombotic risk factors, antithrombotic treatment, and stroke subtypes	['independ', 'contribut', 'risk', 'second', 'ischaem', 'stroke', 'prothrombot', 'risk', 'factor', 'antithrombot', 'treatment', 'stroke', 'subtyp']
385	22335	7.0	0.2331	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Design of randomised trials of unfractionated heparin compared with placebo or untreated control in acute coronary syndrome without ST elevation	['design', 'randomis', 'trial', 'unfraction', 'heparin', 'compar', 'placebo', 'untreat', 'control', 'acut', 'coronari', 'syndrom', 'st', 'elev']
386	25769	7.0	0.2329	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Discrimination between benign and malignant thyroid lesions by CD44v6 and galectin-3 immunodetection on fresh cytological material from preoperative fine-needle aspiration	['discrimin', 'benign', 'malign', 'thyroid', 'lesion', 'cd', 'galectin', 'immunodetect', 'fresh', 'cytolog', 'materi', 'preoper', 'fine', 'needl', 'aspir']
387	26395	7.0	0.2325	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Risk of ischaemic stroke subtypes  *   associated with risk factors	['risk', 'ischaem', 'stroke', 'subtyp', 'associ', 'risk', 'factor']
388	50539	7.0	0.2321	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Germline BRCA mutation status according to tumour BRCA mutation status	['germlin', 'brca', 'mutat', 'status', 'accord', 'tumour', 'brca', 'mutat', 'status']
389	10148	7.0	0.2309	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Multivariable Logistic Regression Predicting the Likelihood of CAD According to Quartiles of LBP Levels, Markers of Systemic Inflammation, and Established Cardiovascular Risk Factors	['multivari', 'logist', 'regress', 'predict', 'likelihood', 'cad', 'accord', 'quartil', 'lbp', 'level', 'marker', 'system', 'inflamm', 'establish', 'cardiovascular', 'risk', 'factor']
390	8857	7.0	0.2309	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Evaluating the Predictive Ability of the HAS-BLED Score Versus CHADS2 or CHA2DS2-VASc Score for the Detection of MajorBleeding Using C-Statistics, Relative NRI, and IDI Indexes	['evalu', 'predict', 'abil', 'bleed', 'score', 'versus', 'chad', 'cha', 'ds', 'vasc', 'score', 'detect', 'majorbleed', 'statist', 'relat', 'nri', 'idi', 'index']
391	27138	7.0	0.2304	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Description of haemostatic gene polymorphisms in this review and their associated intermediate phenotypes	['descript', 'haemostat', 'gene', 'polymorph', 'review', 'associ', 'intermedi', 'phenotyp']
392	38604	7.0	0.23	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Risk of intracerebral haemorrhage according to use of HRT and identified risk factors in women aged 4564 years	['risk', 'intracerebr', 'haemorrhag', 'accord', 'use', 'hrt', 'identifi', 'risk', 'factor', 'women', 'age', 'year']
393	45985	7.0	0.2298	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Prevalence of different risk factors in cryptogenic versus other transient ischaemic attack and ischaemic stroke subtypes	['preval', 'differ', 'risk', 'factor', 'cryptogen', 'versus', 'transient', 'ischaem', 'attack', 'ischaem', 'stroke', 'subtyp']
394	48049	7.0	0.2291	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Women with hormone-receptor-positive tumours and who did not report either symptom at trial entry with vasomotor symptoms or joint symptoms at the 3-month follow-up visit according to treatment group	['women', 'hormon', 'receptor', 'posit', 'tumour', 'report', 'symptom', 'trial', 'entri', 'vasomotor', 'symptom', 'joint', 'symptom', 'month', 'follow', 'visit', 'accord', 'treatment', 'group']
395	7410	7.0	0.2284	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Overview of Used Risk Scores: Risk Factors Used in ATRIA Risk Score	['overview', 'risk', 'score', 'risk', 'factor', 'atria', 'risk', 'score']
396	11898	7.0	0.2284	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Respiratory-chain enzyme activity in circulating lymphocytes of patients 1 and 3 and of 163 controls	['respiratori', 'chain', 'enzym', 'activ', 'circul', 'lymphocyt', 'patient', 'control']
397	47654	7.0	0.2265	risk, associ, factor, control, score, trial, status, accord, distribut, assess	SLC6A3 mutations identified in patients with dopamine transporter deficiency syndrome	['slc', 'mutat', 'identifi', 'patient', 'dopamin', 'transport', 'defici', 'syndrom']
398	23696	7.0	0.2263	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Relative Risk of Incident CAC Associated With Increasing Risk Categories According to FRS and RRS Classification	['relat', 'risk', 'incid', 'cac', 'associ', 'increas', 'risk', 'categori', 'accord', 'frs', 'rrs', 'classif']
399	23697	7.0	0.2262	risk, associ, factor, control, score, trial, status, accord, distribut, assess	Mean Change in CAC Score  (Agatston Units)  Associated With Increasing Risk Categories According to FRS and RRS Classification	['mean', 'chang', 'cac', 'score', 'agatston', 'unit', 'associ', 'increas', 'risk', 'categori', 'accord', 'frs', 'rrs', 'classif']
